Separated peptide

By synthesizing PD-1 peptides and chimeric PD-1 peptides, the PD-1/PD-L1 signal transduction was directly blocked, which solved the problem of low tumor penetrance in antibody therapy, enhanced the anti-tumor immune response, and significantly inhibited tumor growth.

CN118909082APending Publication Date: 2024-11-08OHIO STATE INNOVATION FOUND +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410999144.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-03-28
Filing Date
2018-03-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antibody therapies suffer from low tumor penetrance when targeting the PD-1/PD-L1 signaling pathway, resulting in poor efficacy. Furthermore, many cancer patients do not respond to PD-1/PD-L1 checkpoint blockade therapy, necessitating new PD-1/PD-L1 checkpoint inhibitors.

Method used

Synthetic and chimeric PD-1 peptides containing specific PD-1B and Th epitopes were developed and linked via adapters to stimulate immune responses, directly blocking the interaction between PD-1 and PD-L1 or promoting the production of antibodies that block the PD-1/PD-L1 interaction by the host immune response.

Benefits of technology

These peptides can effectively penetrate tumor tissue, directly block PD-1/PD-L1 signal transduction, improve the efficacy of immunotherapy, enhance anti-tumor immune response, and significantly inhibit tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909082A_ABST
    Figure CN118909082A_ABST
Patent Text Reader

Abstract

The present invention relates to an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 5.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application. The international application number of the original application is PCT / US2018 / 024831, the Chinese national application number is 201880022159.X, the application date is March 28, 2018, and the name of the invention is “Human PD1 peptide vaccine and its use”. Technical Field

[0002] The present invention relates to a human PD1 peptide vaccine and uses thereof. Background Art

[0003] 1. Cancer is currently the leading cause of death in developed countries and worldwide. The economic burden of the disease and, more importantly, the suffering it causes is enormous. There is a clear and urgent need to accelerate the development and application of new and more effective anticancer therapies. The field of oncology is broad and includes several indications, including some rare / orphan forms. Although oncology remains one of the most active areas in drug development, there are still large unmet needs.

[0004] 2. Recent advances in cancer immunology have demonstrated the importance of T cell-mediated antitumor immunity against human cancer, and inhibitory receptors expressed by T cells have become important targets for cancer immunotherapy. Signal transduction through the immune checkpoint programmed cell death protein-1 (PD-1) achieves tumor progression by inhibiting antitumor immune responses. The use of monoclonal antibodies to therapeutically block the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) has shown significant clinical success in cancer treatment and has shown excellent activity in a wide range of cancer subtypes, even in late disease and metastatic stages. Therapeutic agents targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first drugs in the family of checkpoint inhibitors against the PD-1 pathway to receive accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of ipilimumab-refractory melanoma.

[0005] 3. In recent years, monoclonal antibodies targeting immune checkpoints, especially the PD-1 / PD-L1 axis, have achieved amazing results in cancer treatment. Despite their proven effectiveness, antibodies have specific disadvantages as therapeutic agents, including poor tissue / tumor penetrance, which may be particularly relevant when targeting the PD-1:PD-L1 signaling pathway. For example, effector T cells expressing PD-1 have been found to infiltrate solid tissues of tumors expressing PD-L1. This is problematic for antibodies, which are hindered by their larger size and cannot enter the tumor. It is concluded that antibodies may therefore be unable to completely antagonize PD-1:PD-L1 signaling at the intended treatment site within the tumor, resulting in poor efficacy.

[0006] 4. Checkpoint blockade has ushered in a new paradigm shift in cancer immunotherapy. However, many cancer patients do not improve in response to PD-1 / PD-L1 checkpoint blockade. What is needed are new PD-1 / PD-L1 checkpoint inhibitors for the treatment of cancer, viral infections, autoimmune diseases, and Alzheimer's disease. Summary of the invention

[0007] 5. The present invention discloses methods and compositions related to the synthesis of PD-1 peptides.

[0008] 6. In one aspect, disclosed herein is a PD-1 chimeric peptide for stimulating an immune response to a PD-1 protein, the PD-1 chimeric peptide comprising one or more PD-1 B cell epitopes, a helper T cell (Th) epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6), and a linker connecting the PD-1 B cell epitope to the Th epitope (such as, for example, SEQ ID NO: 7), wherein the one or more PD-1 B cell epitopes consist of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

[0009] 7. Also disclosed herein is a chimeric peptide of any of the aforementioned aspects, wherein the peptide comprises an amino acid sequence as shown in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11.

[0010] 8. In one aspect, disclosed herein is a synthetic PD-1 peptide for stimulating an immune response to a PD-1 protein, the synthetic PD-1 peptide comprising one or more of the sequences shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, including the D enantiomer of the disclosed sequence. In one aspect, the synthetic peptide may be acetylated.

[0011] 9. Also disclosed herein is a chimeric peptide comprising the synthetic peptide of any of the foregoing aspects, the chimeric peptide further comprising a Th epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6) and a linker connecting the synthetic PD-1 peptide to the Th epitope (such as, for example, SEQ ID NO: 7).

[0012] 10. Also disclosed herein is a chimeric peptide of any of the aforementioned aspects, wherein the peptide comprises an amino acid sequence as shown in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 or SEQ ID NO: 19.

[0013] 11. In one aspect, disclosed herein is a pharmaceutical composition comprising one or more chimeric peptides or synthetic peptides of any of the preceding aspects and a pharmaceutically acceptable carrier.

[0014] 12. The present invention also discloses a pharmaceutical composition of any of the aforementioned aspects, which further comprises one or more HER-2 B cell epitopes (such as, for example, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30) and / or one or more anti-Her-2 antibodies.

[0015] 13. In one aspect, disclosed herein is a method of treating cancer, Alzheimer's disease, or an autoimmune disease in a subject, the method comprising administering to the subject any of the peptides or compositions of any of the preceding aspects. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] 14. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and, together with the description, illustrate the disclosed compositions and methods.

[0017] 15. Figure 1A and Figure 1B A close-up view of the hPD-1 and hPD-L1 interface, represented by blue and green ribbons, respectively, is shown. All residues important for the interaction are highlighted as sticks. Residues forming the hydrophobic core are colored yellow. Water molecules are shown as red spheres. Hydrogen bonds are depicted as black dashed lines. ( Figure 1A ) Frontal view, Zak et al., 2015, Structure 23, 2341–2348. ( Figure 1B ) modeled PD-1 peptide.

[0018] 16. Figure 2A , Figure 2B and Figure 2C Modeling of the PD-1 peptide according to the conformational epitope is shown. Figure 2A PD-1 (32-50) (SEQ ID NO: 2) is shown. Figure 2B PD-1 (73-90) (SEQ ID NO: 4) is shown. Figure 2C PD-1 (92-110) (SEQ ID NO: 5) is shown.

[0019] 17. Figure 3A , Figure 3B , Figure 3C , Figure 3D and Figure 3E Surface plasmon resonance spectra of binding experiments on the extracellular domain of human hPD-L1 are shown. Figure 3A )、Nivolumab( Figure 3B ), human IgG( Figure 3C ) were 2345RU, 12264RU and 11651RU, respectively. The validation of the sensor chip was demonstrated by measuring the specificity of fhPD-1 and nivolumab binding. 1 μM (17.3 μg / ml) rhPD-1 was injected onto the chip at 10 μl / min for 3 min ( Figure 3D ). 1 μM BSA was used as a negative control. The chip was regenerated with 10 mM glycine hydrochloride (pH 2.5) ( Figure 3E ).

[0020] 18. Figure 4A , Figure 4B , Figure 4C , Figure 4D , Figure 4E and Figure 4F MVF peptide and acetylated peptide binding to rhPD-L1 and nivolumab are shown. MVF-PD-1(45-64), MVF-PD-1(73-90), MVF-PD-1(92-110) bind to immobilized rhPD-L1( Figure 4A ) or nivolumab ( Figure 4B ). Ac-PD-1(45-64), Ac-PD-1(73-90), Ac-PD-1(92-110) bind to immobilized rhPD-L1( Figure 4C and Figure 4D ) or nivolumab ( Figure 4E and Figure 4F ).

[0021] 19. Figure 5A Shown are the 1st (1Y+3), 3rd (2Y+3) and 6th (3Y+3) trial bleeds tested by ELISA on MVF-peptide at 200 ng / well. Sera were first diluted to 1:2000 and then serially diluted on the plate to a maximum of 1:250,000. ABTS was used as the substrate in this assay. Titer was defined as the final dilution that still had an absorbance of >0.200 when read at 415λ.

[0022] 20. Figure 5B The terminal bleed serum is shown to be tested by ELISA on various peptide constructs (MVF-peptide, acetylated peptide, free peptide and recombinant human PD-1 protein) at 200ng / well. The serum is first diluted to 1:2000 and then serially diluted on the plate to a maximum of 1:250,000. ABTS is used as the substrate in this assay. The titer is defined as the final dilution that still has an absorbance of >0.200 when read at 415λ.

[0023] twenty one. Figure 5C Shown is testing of antibodies purified from terminal serum by ELISA on peptide at 200 ng / well. Antibodies were first diluted to 20 μg / ml and then serially diluted to a maximum of 625 ng / ml on a plate. ABTS was used as a substrate in the assay. Titer was defined as the final dilution that still had an absorbance of >0.200 when read at 415λ.

[0024] twenty two. Figure 6 Splenocytes from naive TCR transgenic mice were activated with MBP Ac1-11 for 3 days. PD-1 expression was determined by flow cytometry. Cells were stained with α-mPD-1 or α-hPD-1 antibodies as indicated. Cells were gated on CD4+ T cells.

[0025] twenty three. Figure 7 Purified α-hPD-1 polyclonal antibodies are shown to alter the antigen-specific proliferation of myelin-specific CD4 T cells. (A) Splenocytes from naive TCR transgenic mice were labeled with CFSE and activated with MBP Ac1-11 for 4 days in the presence of 50 mg / ml of αhPD-1 antibody or control rabbit IgG. Cells were gated on CD4+ cells. (B) Overlay of CFSE histograms of cells treated with specific αhPD-1 antibody (blue) and control rabbit IgG (red) in (A).

[0026] twenty four. Figure 8 The protocol for mouse vaccination and tumor implantation is shown. Mice received a total of 3 vaccinations at 3-week intervals. Ten days after the third vaccination, 1×10 5 The mice were challenged with CT26 mouse colon cancer tumor cells. Control mice were inoculated with CT26 cell line and treated with mouse pD-1 monoclonal antibody every 3 days.

[0027] 25. Fig. 9 The immunogenicity of the PD-1 vaccine is shown. The serum pool was tested by ELISA on MVF-peptide at 200 ng / well. Serum concentrations of 1:100-1:250,000 were tested. ABTS was used as substrate in the assay. The titer was defined as the final dilution that still had an absorbance of >0.200 when read at 415λ.

[0028] 26. Figure 10A and Fig. 10BSplenocytes (A) and tumor infiltrating cells (B) isolated from all 5 groups of treated mice are shown. CD4 and CD8 cells were determined by flow cytometry (gated on CD45+CD3+ cells). Foxp3+CD25+CD4 regulatory T cells were determined by intracellular staining. All CD4 and CD8 T cells were gated on CD45+CD3+ cells. Tregs were gated on CD45+CD3+CD4+ cells. Group A = control peptide, Group B = 32-50; Group C = 45-64; Group D = 73-90; Group E = 92-110; Group F = α-mouse PD-1 (positive control).

[0029] 27. Figure 11A, Figure 11B, Figure 11C, Figure 11D, Figure 11E, Fig.11F , Figure 11G and Fig.11H Separate graphs of tumor growth in Balb / c mice (5 / group) immunized with each of the four PD-1 constructs A: (PD-1(32-50), B: PD-1(45-64), C: PD-1(73-90), and D: PD-1(92-110), a control peptide (E: irrelevant peptide), and a positive control group (F) treated with an anti-mouse PD-1 monoclonal antibody. Figures 11G and 11G show tumor growth in each of the four PD-1 constructs A: (PD-1(32-50), B: PD-1(45-64), C: PD-1(73-90), and D: PD-1(92-110), a control peptide (E: irrelevant peptide), and a positive control group (F) treated with an anti-mouse PD-1 monoclonal antibody. Fig.11H Figure 2 shows the immunization with PD-1 vaccine construct and CT26 cancer cells (1×10 5 ) Individual curves for syngeneic Balb / c challenged with . Tumor-bearing mice were monitored twice weekly and scored for the formation of palpable tumors and then sacrificed on day 19.

[0030] 28. Fig. 12A , Fig. 12B , Fig. 12C and Fig.12D The distribution of LWW and LWH measurements on day 14 is shown for MVF-PD-1 (32-50), MVF-PD-1 (45-64), MVF-PD-1 (73-90), and MVF-PD-1 (92-110). LWW (12A) and LWH (12B) are shown for MVF-PD-1 (92-110). Fig. 12C The distribution of LWW14 for each of MVF-PD-1 (32-50), MVF-PD-1 (45-64), MVF-PD-1 (73-90), and MVF-PD-1 (92-110) is shown. Fig.12D The distribution of LWH14 for each of MVF-PD-1 (32-50), MVF-PD-1 (45-64), MVF-PD-1 (73-90), and MVF-PD-1 (92-110) is shown.

[0031] 29. Figure 13A and Fig. 13B αhPD1-45 and αhPD1-73 inhibit myelin-specific proliferation. CFSE-labeled splenocytes specific for MBP Ac1-11 from naive Vα2.3 / Vβ8.2 TCR transgenic mice were activated with MBP Ac1-11 in the presence of 50 μg / ml of αhPD-1 antibody or control rabbit IgG. CFSE was analyzed by flow cytometry (13A). Cells were gated on CD4+ cells. The amount of cells per proliferative generation is summarized in 13B.

[0032] 30. Fig.14 The immunogenicity of the PD-1 vaccine is shown. Pooled sera were tested by ELISA on 200 ng / well MVF-peptide. Serum concentrations of 1:100-1:250,000 were tested. Titers were defined as The final dilution still had an absorbance > 0.200 when read at 4 °C.

[0033] 31. Fig.15 Shown are mean curves of tumor growth in syngeneic Balb / c mice (5 / group) immunized with four PD-1 MVF-vaccine constructs A: (PD-1(32-50), B: PD-1(45-64), C: PD-1(73-90) and D: PD-1(92-110), E: -ve control (irrelevant peptide); F: +ve control anti-mouse PD-1 monoclonal antibody (29F.1A12). Mice were challenged with CT26 cancer cells (1×105) 15 days after the third vaccination. Mice were monitored twice a week and the formation of palpable tumors was scored, and tumors were measured using calipers. Animals were sacrificed on day 19.

[0034] 32. Fig.16 Shown is a schedule for combined vaccination in BALB / c followed by attack with CT26 / HER-2 cancer cells. The CT-26-HER-2 tumor model in Balb / c is used to test the synergistic effect of anti-PD1 immunotherapy combined with anti-HER2 immunotherapy. Peptide vaccines are given alone or in combination as indicated. The vaccine is dissolved in water and emulsified in MontanideISA 720 (1:1) and 50 μg nor-MDP (N-acetylglucosamine-3-yl-acetyl-l-alanyl-d-isoglutamine). Mice receive a total of 3 vaccinations at 3-week intervals. Female Balb / c mice (Charles River Laboratories) aged 5 to 6 weeks were immunized three times with 100 μg of each peptide vaccine at 3-week intervals, and 2 weeks after the third immunization, CT-26-HER-2neu tumor cells (1×105 Mice were challenged with 100 cells / mouse. Balb / c mice were treated with anti-mouse PD-1 MAb 29F.1A12 (Bio X Cell, West Lebanon, NH) twice a week. 200 μg / dose was used as a positive control or pbs was used as a negative control. Mice were monitored twice a week and the formation of palpable tumors was scored for up to 21 days, and then mice were sacrificed when the tumor was necrotic or exceeded a predetermined size of 2,000 mm3. Tumor volume (in cubic millimeters) was measured using a caliper and calculated using the following formula: A×B2×0.5, where A is the maximum diameter and B is the minimum diameter.

[0035] V = [(length × width2) / 2].

[0036] During the immunization period, blood was drawn every two weeks and used for ELISA to monitor Ab titers. At the end of the treatment, mice were euthanized, tumors were extracted and weighed, and samples of tumors were preserved for further study and histological examination. Spleen was also collected for further examination. All experiments were performed in accordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the approval of the Ohio State University Institutional Animals Care and Use Committee was obtained, and the scheme accepted was described in detail.

[0037] 33. Fig.17 The immunogenicity of the individual antigens in mice treated with the triple vaccine is shown. The serum pool taken from mice immunized with 3 peptides (HER-2 (266-296), HER-2 (597-626) and PD-1 (92-110)) was tested by ELISA on MVF-peptide at 200ng / well. Serum concentrations of 1:100-1:512,000 were tested. ABTS was used as a substrate in the assay, and the enzyme reaction was stopped with a 0.1% SDS solution after 10 minutes. The titer was defined as the final dilution that still had an absorbance of>0.200 when read at 415nm. Serum samples 1Y+3, 2Y+1, 2Y+3 and 3Y+2 were collected before CT-26HER-2neu tumor attack. Samples 3Y+3 and 3Y+5 were collected 1 week and 3 weeks after attack, respectively.

[0038] 34. Fig.18It was shown that triple HER-2(266)+HER-2(597)+PD-1(92) vaccination caused significant (p<0.001) tumor growth inhibition in BALB / c challenged with colon cancer cell line CT26 / HER-2 compared with positive control α-mouse PD-1 mAb (29F.1A12), MVF-PD-1(92-110), negative control PBS or irrelevant peptide.

[0039] 35. Fig.19A and Fig.19B The combined HER-2 and PD-1 vaccine showed enhanced immunogenicity and tumor growth inhibition. Graph of tumor growth in syngeneic Balb / c mice (10 / group) immunized 3 times at 3-week intervals with PD-1 (92-110) alone, with two HER-2 peptide immunogens combined, or with HER-2 immunogens alone. CT-26 HER-2 cancer cells (1×10 5 ) challenged mice. PBS (negative control) was challenged with tumors and then treated with IP injections of PBS twice a week. Mice were monitored and the formation of palpable tumors was scored and then measured regularly using calipers. Error bars are representations of the standard error of the group of mice, and p values ​​compare each group to the negative control PBS-treated mice.

[0040] 36. Figure 20A, Figure 20B, Figure 20C and Fig.20D Isolation of TILs from each mouse in the 4 groups is shown. CD4 (20A) and CD8 (20B) T cells were determined by flow cytometry (gated on CD45+ cells). Foxp3+CD25+CD4 Tregs (0C) were determined by intracellular staining (gated on CD45+CD4+ cells). Fig.20D CD8 + Ratio of T cells to T regs. Group means were calculated and compared using analysis of variance.

[0041] 37. Figure 21A and Fig.21B Analysis of tumor infiltrating lymphocytes taken from mice vaccinated with peptide vaccines is shown. FIG. 21A shows combined data from the first in vivo experiment and Groups 5 and 6 from the second in vivo experiment. Tumor infiltrating cells were isolated from combined tumor tissues of the 5 groups (Groups A to F) of treated mice in the first in vivo experiment. Tumor infiltrating cells were isolated from each mouse in Groups 5 and 6 from the second in vivo experiment. CD4 and CD8 cells were determined by flow cytometry (gated on CD45+ infiltrating cells). FoxP3 expression on CD25+CD4+T cells was determined by intracellular staining (gated on CD45+CD4+ cells). Fig.21BShown is the separation of tumor infiltrating cells from each mouse in group 1-4 of the second in vivo experiment. CD4 and CD8 cells were determined by flow cytometry (gate at CD45+ infiltrating cells). FoxP3 expression on CD25+CD4+T cells was determined by intracellular staining (gate at CD45+CD4+ cells). Group means were calculated and compared using analysis of variance. Error bars represent standard error of the mean (sem). DETAILED DESCRIPTION

[0042] 38. It should be understood that before the compounds, compositions, articles, devices and / or methods of the present invention are disclosed and described, it should be understood that they are not limited to specific synthetic methods or specific recombinant biotechnology methods unless otherwise specified, or to specific reagents unless otherwise specified, and therefore can certainly vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.

[0043] A. Definition

[0044] 39. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, etc.

[0045] 40. In this article, ranges can be expressed as from "about" a specific value, and / or to "about" another specific value. When such a range is expressed, another embodiment includes from a specific value and / or to other specific values. Similarly, when the value is expressed as an approximate value with "about" in the front, it should be understood that the specific value constitutes another embodiment. It should also be understood that the end value of each range is meaningful relative to another end value and independently of another end value. It should also be understood that many values ​​are disclosed herein, and in addition to the value itself, each value is also disclosed herein as "about" the specific value. For example, if the value "10" is disclosed, "about 10" is also disclosed. It should also be understood that when a value is disclosed, "less than or equal to" the value, "greater than or equal to" the value, and the possible range between the values ​​is also disclosed, as appropriately understood by those skilled in the art. For example, if the value "10" is disclosed, "less than or equal to 10" and "greater than or equal to 10" are also disclosed. It should also be understood that throughout the application, data is provided in a variety of different formats and that the data represents endpoints and starting points, as well as ranges for any combination of data points. For example, if a specific data point "10" and a specific data point 15 are disclosed, it should be understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15, as well as between 10 and 15, are considered disclosed. It should also be understood that every unit between two specific units is also disclosed. For example, if 10 and 15 are disclosed, 11, 12, 13, and 14 are also disclosed.

[0046] 41. In this specification and the claims that follow, reference will be made to a number of terms which shall be defined as having the following meanings:

[0047] 42. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not occur.

[0048] 43. The term "administering" refers to oral, topical, intravenous, subcutaneous, transdermal, transdermal, intramuscular, intraarticular, parenteral, intraarteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal administration by inhalation or via an implanted reservoir. The term "parenteral" includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

[0049] 44. As used herein, the term "comprising" is intended to mean that compositions and methods include the recited elements, but do not exclude other elements. "Consisting essentially of" when used to define compositions and methods shall mean excluding other elements that are of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from separation and purification methods and pharmaceutically acceptable carriers (such as phosphate buffered saline, preservatives, etc.). Embodiments defined by each of these transition terms are within the scope of the invention.

[0050] 45. An "effective amount" is an amount sufficient to achieve beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosings.

[0051] 46. ​​As used herein, the terms "treat," "treating," "treatment," and grammatical variations thereof include partially or completely delaying, alleviating, relieving, or reducing the intensity of one or more associated symptoms of a disorder or condition, and / or alleviating, alleviating, or hindering one or more causes of a disorder or condition. Treatment according to the present invention may be applied preventively, prophylactically, palliatively, or therapeutically. In some cases, the terms "treat," "treating," "treatment," and grammatical variations thereof include partially or completely reducing the size of a tumor, reducing the number of tumors, and reducing the severity / metastatic ability of a tumor compared to the subject prior to treatment or compared to the incidence of such symptoms in the general population or study population.

[0052] 47. The term "inhibit" refers to a decrease in activity, response, condition, disease or other biological parameter. This may include, but is not limited to, complete ablation of the activity, response, condition or disease. For example, this may also include a 10% decrease in activity, response, condition or disease compared to a natural or control level. Thus, the decrease may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any decrease therebetween compared to a natural or control level.

[0053] 48. As used herein, "subject" means an individual. Thus, "subject" may include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), experimental animals (e.g., mice, rabbits, rats, guinea pigs, etc.), and birds. "Subject" may also include mammals, such as primates or humans.

[0054] 49. "Reduce" or other forms of the word, such as "reduce" or "reduced" means to make an event or characteristic (e.g., tumor growth) decrease. It should be understood that this is usually related to some standard or expected value, in other words, it is relative, but it is not always necessary for the standard or relative value to be mentioned. For example, "reduce tumor growth" means that the growth rate of the tumor is reduced relative to a standard or control.

[0055] 50. "Prevent" or other forms of the word, such as "preventing" or "prevention" means to stop a particular event or characteristic, to stabilize or slow the development or progression of a particular event or characteristic, or to minimize the likelihood of a particular event or characteristic occurring. Prevention does not need to be compared to a control because it is usually more absolute than, for example, reduction. As used herein, something can be reduced but not prevented, but something that is reduced can also be prevented. Similarly, something can be prevented but not reduced, but something that is prevented can also be reduced. It should be understood that unless otherwise expressly indicated, where reduce or prevent is used, the use of the other words is also expressly disclosed.

[0056] 51. References in the specification and the subsequent claims to parts by weight of a particular ingredient or component in a composition refer to the weight relationship of that ingredient or component to any other ingredient or component in the composition or article expressed as parts by weight. Thus, in a compound comprising 2 parts by weight of component X and 5 parts by weight of component Y, X and Y are present in a weight ratio of 2:5, and are present in that ratio regardless of whether other components are present in the compound. As used herein, unless expressly indicated to the contrary, "weight %" or "weight percent" of a component refers to the ratio of the weight of the component to the total weight of the composition containing the component, expressed as a percentage.

[0057] 52. Various publications are cited throughout this application. The disclosures of these publications are hereby incorporated by reference in their entireties into this application to more fully describe the state of the art to which they pertain. The materials contained in the references disclosed are also individually and specifically incorporated by reference herein, and these materials are discussed in the sentences in which the references are based.

[0058] B. Composition

[0059] 53. Components for preparing the disclosed compositions and the compositions themselves used within the methods disclosed herein are disclosed. These and other materials are disclosed herein, and it should be understood that when combinations, subgroups, interactions, groups, etc. of these materials are disclosed, each is specifically contemplated and described herein, even though specific references to each of the various individual and collective combinations and arrangements of these compounds may not be explicitly disclosed. For example, if a specific synthetic or chimeric PD-1 peptide is disclosed and discussed, and many modifications that can be made to many molecules including the synthetic or chimeric PD-1 peptide are discussed, each combination and arrangement of the synthetic or chimeric PD-1 peptide and possible modifications are specifically contemplated unless the contrary is explicitly stated. Thus, if a class of molecules A, B, and C and a class of molecules D, E, and F are disclosed, and an example of a combined molecule AD is disclosed, then even if each is not listed individually, each is a combination of the meanings that are contemplated individually and in their entirety, and AE, AF, BD, BE, BF, CD, CE, and CF are also considered disclosed. Likewise, any subgroup or combination of these is also disclosed. Thus, for example, a subgroup of AE, BF, and CE would be considered disclosed. This concept applies to all aspects of this application, including but not limited to steps in methods of making and using the disclosed compositions. Thus, if there are various additional steps that can be performed, it should be understood that each of these additional steps can be performed using any specific embodiment or combination of embodiments of the disclosed methods.

[0060] 54. The PD-1 gene, which belongs to the immunoglobulin superfamily, encodes a 55kDa type I transmembrane protein. Both mouse PD-1 and human PD-1 consist of 288 amino acids and have an N-terminal signal peptide (20 amino acids) and a hydrophobic region in the middle part (which is a transmembrane region). Human and mouse PD-1 proteins have about 60%-80% amino acid identity, and four potential N-glycosylation sites and residues that define the Ig-V domain are conserved. PD-1 is expressed on T cells, B cells, and macrophages. The ligands of PD-1 are B7 family members PD-L1 (B7-H1) and PD-L2 (B7-DC). Signal transduction through the immune checkpoint programmed cell death protein-1 (PD-1) achieves tumor progression by inhibiting anti-tumor immune responses. The use of monoclonal antibodies to therapeutically block the signaling axis between PD-1 and its ligand, programmed cell death ligand-1 (PD-L1), has shown remarkable clinical success in cancer treatment and has demonstrated excellent activity across a broad set of cancer subtypes. Disclosed herein are improvements over traditional PD-1 / PD-L1 blockade using smaller, non-antibody peptide therapeutics and peptide vaccines that directly block the interaction of PD-1 and PD-L1 or that can stimulate a host immune response to produce antibodies against PD-1 that block the PD-1 / PD-L1 interaction.

[0061] 55. Using computer-assisted analysis of PD-1 B cell epitopes, sequences corresponding to residues 32-50, 45-64, 73-90, and 92-110 of PD-1 (SEQ ID NO: 1) were derived. Therefore, in one aspect, synthetic PD-1 peptides for stimulating an immune response to a PD-1 protein are disclosed herein, comprising residues 32-50, 45-64, 73-90, and / or 92-100 of PD-1. For example, synthetic PD-1 peptides for stimulating an immune response to a PD-1 protein are disclosed herein, comprising VLNWYRMSPSNQTDKLAAF (SEQ ID NO: 2), KLAAFPEDRSQPGQDCRFR (SEQ ID NO: 3), DFHMSVVRARRNDSGTYL (SEQ ID NO: 4), and / or GAISLAPKAQIKESLRAEL (SEQ ID NO: 5). In one aspect, these peptides may be acylated and / or amidated. Accordingly, disclosed herein are synthetic PD-1 peptides for stimulating an immune response to a PD-1 protein, the synthetic PD-1 peptides comprising (SEQ ID NO: 2), (SEQ ID NO: 3), (SEQ ID NO: 4) and / or (SEQ ID NO: 5); wherein the synthetic peptides are acylated and / or amidated.

[0062] 56. In some cases, the use of analogs of L-amino sequences may have advantages over the base sequence, such as resistance to degradation, stability, ease of synthesis, or greater therapeutic efficacy. In one aspect, it is understood and contemplated herein that the disclosed synthetic sequences may comprise L-amino sequences in reverse order from the amino terminus to the carboxyl terminus. For example, the reverse sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 are FAALKDTQNSPSMRYWNLV (SEQ ID NO: 12), RFRCDQGPQSRDEPFAALK (SEQ ID NO: 13), LYTGSDNRRARVVSMHFD (SEQ ID NO: 14), and LEARLSEKIQAKPALSIAG (SEQ ID NO: 15), respectively. These reverse sequences may also have a mirror image conformation of the base sequence. Therefore, disclosed herein are synthetic PD-1 peptides comprising one or more of the sequences shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and / or SEQ ID NO: 15. As with SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5; the synthetic peptides comprising SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and / or SEQ ID NO: 15 may be acetylated and / or amidated.

[0063] 57. In addition to the reverse analogs of the L-amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 (which are shown in SEQ ID NO 12, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15), there are also D enantiomeric analogs of the forward L-amino (SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5) and reverse L-amino sequences (SEQ ID NO 12, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15), which D enantiomeric analogs may have enhanced resistance to degradation and proteolysis allowing for better oral administration, prolonged therapeutic efficacy and increased synthetic convenience. Thus, in one aspect, disclosed herein is a synthetic PD-1 peptide comprising one or more of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO 12, SEQ ID NO: 13, SEQ ID NO: 14 and / or SEQ ID NO: 15; wherein the amino acids constituting the sequence are D amino acids.

[0064] 58. In one aspect, it is understood and contemplated herein that the disclosed synthetic PD-1 peptides can have enhanced B cell stimulation by linking the synthetic PD-1 peptide to a helper T (Th) cell epitope (i.e., a promiscuous Th cell epitope) that promotes the release of cytokines that help bypass MHC restriction to form a chimeric PD-1 peptide. For example, in one aspect, disclosed herein is a PD-1 chimeric peptide for stimulating an immune response to a PD-1 protein, the PD-1 chimeric peptide comprising one or more PD-1 B cell epitopes and further comprising a helper T cell (Th) epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6), wherein the one or more PD-1 B cell epitopes are selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and / or SEQ ID NO: 15. It is understood and contemplated herein that the B cell epitope (i.e., PD-1 synthetic peptide) can comprise D amino acids.

[0065] 59. The length of a Th epitope may be from about 14 to about 22, more preferably from about 15 to 21, most preferably 16 amino acids. Preferably, the Th cell epitope has one of the following amino acid sequences provided in Table 1.

[0066] Table 1

[0067] Peptide name sequence SEQ ID NO: MVF KLLSLIKGVIVHRLEGVE 6 TT NSVDDALINSTIYSYFPSV 20 TT1 PGINGKAIHLVNNQSSE 21 P2 QYIKANSKFIGITEL 22 P30 FNNFTVSFWLRVPKVSASHLE 23 MVF (natural) LSEIKGVIVHRLEGV 24 HBV FFLLTRILTIPQSLN 25 CSP TCGVGVRVRSRVNAANKKPE 26

[0068] 60. In order to connect the synthetic PD-1 peptide and the Th cell epitope, an amino acid linker can be used. Preferably, the linker is a peptide of about 2 to about 15 amino acids in length, more preferably about 2 to about 10 amino acids, and most preferably about 2 to about 6 amino acids. The most preferred linker comprises the amino acid sequence Gly-Pro-Ser-Leu (SEQ ID NO: 7). Therefore, in one aspect, a chimeric peptide comprising a synthetic peptide of any of the aforementioned aspects is also disclosed herein, the chimeric peptide also comprising a Th epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6) and a linker (such as, for example, SEQ ID NO: 7) that connects the synthetic PD-1 peptide to the Th epitope. For example, in one aspect, disclosed herein is a chimeric PD-1 peptide for stimulating an immune response to a PD-1 protein, the chimeric PD-1 peptide comprising one or more PD-1 B cell epitopes, a helper T cell (Th) epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6), and a linker connecting the PD-1 B cell epitope to the Th epitope (such as, for example, SEQ ID NO: 7); wherein the chimeric PD-1 peptide comprises KLLSLIKGVIVHRLEGVEGPSLVLNWYRMSPSNQTDKLAAF (SEQ ID NO: 8), KLLSLIKGVIVHRLEGVEGPSLKLAAFPEDRSQPGQDCRFR (SEQ ID NO: 9), KLLSLIKGVIVHRLEGVEGPSLDFHMSVVRARRNDSGTYL (SEQ ID NO: 10), KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL (SEQ ID NO: 11), KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL (SEQ ID NO: 12), KLLSLIKGVIVHRLEGVEGPSLVLNWYRMSPSNQTDKLAAF (SEQ ID NO: 13), KLLSLIKGVIVHRLEGVEGPSLKLAAFPEDRSQPGQDCRFR (SEQ ID NO: 14), KLLSLIKGVIVHRLEGVEGPSLDFHMSVVRARRNDSGTYL (SEQ ID NO: 15), KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL (SEQ ID NO: 16), KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL (SEQ ID NO: 17), KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL (SEQ ID NO: 18), KLLSLIKG NO:11), KLLSLIKGVIVHRLEGVEGPSLFAALKDTQNSPSMRYWNLV (SEQ ID NO:16), KLLSLIKGVIVHRLEGVEGPSLRFRCDQGPQSRDEPFAALK (SEQ ID NO:17), KLLSLIKGVIVHRLEGVEGPSLLYTGSDNRRARVVSMHFD (SEQ ID NO:18) and / or KLLSLIKGVIVHRLEGVEGPSLLEARLSEKIQAKPALSIAG (SEQ ID NO:19).

[0069] 61. As with synthetic peptides, it is understood and contemplated herein that the amino acids of the synthetic PD-1 peptides contained within the chimeric PD-1 peptides may be D amino acid analogs of the L-amino acids in the sequence. Thus, in one aspect, disclosed herein are chimeric peptides comprising any of the synthetic PD-1 peptides disclosed herein, further comprising a Th epitope (e.g., a measles virus fusion protein peptide, such as SEQ ID NO: 6) and a linker (such as, for example, SEQ ID NO: 7) that connects the synthetic PD-1 peptide to the Th epitope. For example, in one aspect, disclosed herein are chimeric PD-1 peptides comprising an amino acid sequence as shown in SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and / or SEQ ID NO: 19; wherein the synthetic PD-1 peptide sequence (i.e., a B cell epitope) comprises a D amino acid.

[0070] 1. Sequence Similarity

[0071] 62. It should be understood that, as discussed herein, the terms homology and identity are used in the same way as similarity. Thus, for example, if the word homology is used between two non-natural sequences, it should be understood that this does not necessarily indicate an evolutionary relationship between the two sequences, but rather is studying the similarity or relatedness between their nucleic acid sequences. Many of the methods used to determine homology between two evolutionarily related molecules are generally applicable to any two or more nucleic acids or proteins in order to measure sequence similarity, regardless of whether they are evolutionarily related.

[0072] 63. Generally speaking, it should be understood that any known variants and derivatives of the genes and proteins disclosed herein or any known variants and derivatives that may occur are defined by defining variants and derivatives in terms of homology with specific known sequences. This identity of the specific sequences disclosed herein is also discussed elsewhere herein. Generally speaking, the variants of the genes and proteins disclosed herein usually have at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with the sequence or native sequence. Those skilled in the art will readily understand how to determine the homology of two proteins or nucleic acids such as genes. For example, homology can be calculated after aligning two sequences so that the homology is at its highest level.

[0073] 64. Another method of calculating homology can be performed by a public algorithm. The best alignment of sequences for comparison can be performed by the local homology algorithm of "Smith and Waterman, Adv. Appl. Math. 2: 482 (1981)", by the homology alignment algorithm of "Needleman and Wunsch, J. Mol Biol. 48: 443 (1970)", by the search similarity method of "Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444 (1988)", by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

[0074] 65. It should be understood that generally any method can be used, and that in some cases the results of these different methods may differ, but one skilled in the art will understand that if at least one of these methods finds identity, then the sequence can be said to have that identity and is disclosed herein.

[0075] 66. For example, as used herein, a sequence having a specific percentage homology with another sequence refers to a sequence having the homology calculated by any one or more of the above-mentioned calculation methods. For example, if the first sequence is calculated to have 80% homology with the second sequence using the Zuker calculation method, then the first sequence has 80% homology with the second sequence (as defined herein), even if the first sequence calculated according to any other calculation method does not have 80% homology with the second sequence. For another example, if the first sequence is calculated to have 80% homology with the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method, then the first sequence has 80% homology with the second sequence (as defined herein), even if the first sequence calculated according to the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation method, or any other calculation method does not have 80% homology with the second sequence. As another example, if a first sequence is calculated to have 80% homology with a second sequence using each calculation method, then the first sequence is 80% homologous (as defined herein) to the second sequence (although in reality, different calculation methods will typically result in different calculated homology percentages).

[0076] 2. Peptides

[0077] a) Protein and peptide variants

[0078] 67. As discussed herein, there are many known and herein contemplated variants of synthetic PD-1 peptides and chimeric PD-1 peptides. In addition to known functional PD-1 strain variants, there are derivatives of synthetic PD-1 peptides and chimeric PD-1 peptides that also work in the disclosed methods and compositions. Protein variants and derivatives are well known to those skilled in the art and may involve amino acid sequence modifications. For example, amino acid sequence modifications generally belong to one or more of the three categories of substitution variants, insertion variants, or deletion variants. Insertions include amino and / or carboxyl terminal fusions and intrasequence insertions of single or multiple amino acid residues. Insertions are typically smaller insertions than those of amino or carboxyl terminal fusions, for example, about one to four residues. Immunogenic fusion protein derivatives, such as those described in the examples, are prepared by fusing sufficiently large polypeptides to confer immunogenicity to the target sequence by in vitro cross-linking or by transforming recombinant cell cultures with DNA encoding the fusion. The deletion is characterized by removing one or more amino acid residues from the protein sequence. Typically, no more than about 2 to 6 residues are deleted at any one site within the protein molecule. These variants are usually prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby generating DNA encoding the variant, and then expressing the DNA in a recombinant cell culture. The technology of performing substitution mutations at predetermined sites in DNA with known sequences is well known, such as M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are usually single residues, but can occur at multiple different positions simultaneously; insertions will usually be about 1 to 10 amino acid residues; and deletions will be in the range of about 1 to 30 residues. Deletions or insertions are preferably performed in adjacent pairs, i.e., 2 residues are deleted or 2 residues are inserted. Substitution, deletion, insertion, or any combination thereof can be combined to obtain the final configuration. Mutations must not place the sequence outside the reading frame, and preferably will not form complementary regions that can produce secondary mRNA structures. Substitution variants are variants in which at least one residue has been removed and different residues have been inserted in its place. These substitutions are usually performed according to Tables 2 and 3 below, and are referred to as conservative substitutions.

[0079] Table 2: Amino Acid Abbreviations

[0080]

[0081] Table 3: Amino Acid Substitutions Exemplary conservative substitutions for original residues and others are known in the art.

[0082]

[0083] 68. Significant changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 3, i.e., by selecting residues that have a more significant effect on maintaining (a) the structure of the polypeptide backbone in the area of ​​the substitution (e.g., a sheet or helical conformation), (b) the charge or hydrophobicity of the molecule at the target site, or (c) a large portion of the side chain. Substitutions that would generally be expected to produce the greatest changes in protein properties are those in which (a) a hydrophilic residue (e.g., seryl or threonyl) is replaced by (or with) a hydrophobic residue (e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl); (b) a cysteine ​​or proline is replaced by (or with) any other residue; (c) a residue having a positively charged side chain (e.g., lysyl, arginyl, or histidyl) is replaced by (or with) a negatively charged residue (e.g., glutamyl or aspartyl); or (d) a residue having a bulky side chain (e.g., phenylalanine) is replaced by (or with) a residue having no side chain (e.g., glycine), in which case (e) substitutions that increase the number of sites available for sulfation and / or glycosylation.

[0084] 69. For example, replacing one amino acid residue with another amino acid residue that is biologically and / or chemically similar is a conservative substitution known to those skilled in the art. For example, a conservative substitution replaces one hydrophobic residue with another hydrophobic residue, or replaces one polar residue with another polar residue. Substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variants of each explicitly disclosed sequence are included in the mosaic polypeptides provided herein.

[0085] 70. Substitution or deletion mutagenesis can be used to insert sites for N-glycosylation (Asn-X-Thr / Ser) or O-glycosylation (Ser or Thr). It may also be necessary to delete cysteine ​​or other unstable residues. Deletion or substitution of potential proteolytic sites (e.g., Arg) is accomplished, for example, by deleting a basic residue or replacing a basic residue with a glutaminyl or histidyl residue.

[0086] 71. Some post-translational derivatizations are the result of the effect of recombinant host cells on expressed polypeptides. Glutaminyl and asparaginyl residues are often deamidated to corresponding glutamyl and asparaginyl residues after translation. Alternatively, these residues are deamidated under mild acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco pp79-86

[1983] ), acetylation of the N-terminal amine and in some cases, amidation of the C-terminal carboxyl group.

[0087] 72. It will be appreciated that one way to define variants and derivatives of the proteins disclosed herein is by defining the variants and derivatives in terms of homology / identity to a particular known sequence. Variants of these and other proteins disclosed herein are specifically disclosed that have at least 70% or 75% or 80% or 85% or 90% or 95% identity to said sequence. One skilled in the art will readily understand how to determine the homology of two proteins. For example, homology can be calculated after aligning the two sequences such that the homology is at its highest level.

[0088] 73. Another method of calculating homology can be performed by a public algorithm. The best alignment of sequences for comparison can be performed by the local homology algorithm of "Smith and Waterman, Adv. Appl. Math. 2: 482 (1981)", by the homology alignment algorithm of "Needleman and Wunsch, J. Mol Biol. 48: 443 (1970)", by the search similarity method of "Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444 (1988)", by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

[0089] 74. The same type of nucleic acid homology can be obtained by the algorithms disclosed in, for example, "Zuker, M., Science 244: 48-52, 1989", "Jaeger et al., Proc. Natl. Acad. Sci. USA 86: 7706-7710, 1989", and "Jaeger et al., Methods Enzymol, 183: 281-306, 1989".

[0090] 75. It will be appreciated that the descriptions of conservative mutations and homology may be combined together in any combination, such as embodiments having at least 70% homology to a particular sequence, wherein the variant is a conservative mutation.

[0091] 76. Since this specification discusses various proteins and protein sequences, it should be understood that nucleic acids that can encode those protein sequences are also disclosed. This will include all degenerate sequences associated with a specific protein sequence, that is, all nucleic acids with sequences encoding a specific protein sequence and all nucleic acids encoding variants and derivatives of the disclosed protein sequences, including degenerate nucleic acids. Therefore, although each specific nucleic acid sequence may not be written out herein, it should be understood that each sequence is actually disclosed and described herein by the disclosed protein sequence. It should also be understood that although there is no amino acid sequence indicating what specific DNA sequence encodes the protein in the organism, in the case of a specific variant of the disclosed protein disclosed herein, the known nucleic acid sequence encoding the peptide or protein is also known and disclosed and described herein.

[0092] 77. It should be understood that there are many amino acids and peptide analogs that can be incorporated into the disclosed compositions. For example, there are many D amino acids or amino acids with functional substituents that are different from the amino acids shown in Tables 2 and 3. Disclosed are the opposite stereoisomers of naturally occurring peptides, as well as stereoisomers of peptide analogs. These amino acids can be readily incorporated into polypeptide chains by engineering genetic constructs that add tRNA molecules with the selected amino acids and insert the analog amino acids into the peptide chain in a site-specific manner using, for example, amber codons.

[0093] 78. Molecules that resemble peptides but are not linked via natural peptide bonds can be produced. For example, the bonds of amino acids or amino acid analogs may include CH 2 NH-, -CH 2 S-、-CH 2 -CH 2 -, -CH=CH- (cis and trans), -COCH 2 -、-CH(OH)CH 2 -and-CHH 2SO- (These bonds and others can be seen in the following references: Spatola, AF, "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins", edited by B. Weinstein, Marcel Dekker, New York, page 267, 1983; Spatola, AF, Vega Data, March 1983, Vol. 1, No. 3, "Peptide Backbone Modifications (general review)"; Morley, Trends Pharm Sci, 1980, pages 463-468; Hudson, D. et al., Int J Pept Prot Res, No. 14, pages 177-185, 1979 (-CH 2 NH-、CH 2 CH 2 -); Spatola et al., Life Sci, vol. 38, pp. 1243-1249, 1986 (-CH H 2 -S); Hann, J. Chem. Soc Perkin Trans., Vol. I, pp. 307-314, 1982 (-CH-CH-, cis and trans); Almquist et al., J. Med. Chem., Vol. 23, pp. 1392-1398, 1980 (-COCH 2 -); Jennings-White et al., Tetrahedron Lett, vol. 23, p. 2533, 1982 (-COCH 2 -); Szelke et al., European Appln, EP 45665CA, 1982, No. 97, p. 39405, 1982 (-CH(OH)CH 2 -); Holladay et al., Tetrahedron. Lett, vol. 24, pp. 4401-4404, 1983 (-C(OH)CH 2 -); and Hruby, Life Sci, vol. 31, pp. 189-199, 1982 (-CH 2 -S-); each of which is incorporated herein by reference. A particularly preferred non-peptide bond is -CH 2 NH-. It will be appreciated that peptide analogs may have more than one atom between bond atoms, such as b-alanine, g-aminobutyric acid, and the like.

[0094] 79. Amino acid analogs and analogs and peptide analogs generally have enhanced or desired properties, such as more economical production, better chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., broad spectrum of biological activity), reduced antigenicity, etc.

[0095] 80.D-amino acids can be used to produce more stable peptides because D amino acids are not recognized by peptidases and the like. Systematically replacing one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., replacing L-lysine with D-lysine) can be used to produce more stable peptides. In other words, flipping (i.e., D-amino acid substitution) of any disclosed sequence is contemplated herein. Cysteine ​​residues can be used to cyclize or link two or more peptides together. This is beneficial for restricting the peptide to a specific conformation. In one aspect, disclosed herein is a synthetic PD-1 peptide comprising one or more of the sequences shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5; wherein the amino acids of the peptide are D enantiomers.

[0096] 81. In one aspect, the disclosed synthetic peptides may be in reverse order, such that the amino-terminus to the carboxyl-terminus of the peptide is reversed (i.e., reverse sequence). In one aspect, the reverse sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 are disclosed herein, which comprise SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively. These reverse sequences may also have a mirror image conformation of the base sequence. In one aspect, the reverse sequence may also comprise a D amino acid substitution (i.e., reverse-flipped) sequence. Therefore, disclosed herein are synthetic PD-1 peptides comprising one or more of the sequences shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15; wherein the amino acids of the peptide are D enantiomers.

[0097] 82. It should be understood that any D amino acid substituted synthetic peptide disclosed herein can be used as a PD-1 epitope in the disclosed PD-1 chimeric peptide. For example, disclosed herein is a chimeric PD-1 peptide comprising one or more PD-1 B cell epitopes, a helper T cell (Th) epitope, and a linker connecting the PD-1 B cell epitope to the Th epitope, wherein the one or more PD-1 B cell epitopes consist of a sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; and wherein the amino acids of the peptide are D enantiomers. In one aspect, disclosed herein is a chimeric PD-1 peptide, wherein the peptide comprises an amino acid sequence as shown in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:19; and wherein the amino acids of the synthetic PD-1 peptide are D enantiomers.

[0098] 3. Drug carrier / drug product delivery

[0099] 83. As described above, the synthetic PD-1 peptides and chimeric PD-1 peptides disclosed herein can also be administered in vivo in a pharmaceutically acceptable carrier. Therefore, in one aspect, disclosed herein is a pharmaceutical composition comprising any one or more of the PD-1 peptides as shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and / or SEQ ID NO: 19.

[0100] 84. The term "pharmaceutically acceptable" refers to a material that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject together with a nucleic acid or a vehicle without causing any undesirable biological effect or interacting in a deleterious manner with any other component of a pharmaceutical composition containing it. The carrier is naturally selected to minimize any degradation of the active ingredient and to minimize any adverse side effects to the subject, as is well known to those skilled in the art.

[0101] 85. It is understood and contemplated herein that the disclosed PD-1 peptides constituting the pharmaceutical compositions are particularly useful for treating diseases or conditions in which PD-1-mediated immunosuppression occurs. Thus, in one aspect, the disclosed pharmaceutical compositions comprising one or more PD-1 peptides disclosed herein can be used in combination with disease-specific treatments or vaccines to further enhance the efficacy of the PD-1 peptides. For example, a pharmaceutical composition comprising one or more PD-1 peptides can be used in combination with an anti-HER2 antibody or a HER-2 B cell epitope for the treatment, inhibition and / or prevention of breast cancer. Thus, in one aspect, disclosed herein is a pharmaceutical composition comprising one or more of the PD-1 peptides, synthetic peptides, or chimeric peptides disclosed herein (e.g., SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and / or SEQ ID NO: 19), and further comprising one or more HER-2 B cell epitopes (e.g., SEQ ID NO: 27 or 29 or a chimeric epitope SEQ ID NO: 28 or 30) and / or an anti-Her-2 antibody. In one aspect, specifically disclosed herein is a pharmaceutical composition comprising MVF-PD1 (92-110) as shown in SEQ ID NO: 11; MVF-HER-2 (266-296) peptide (e.g., as shown in SEQ ID NO: 28) and MVF-HER-2 (597-626) peptide (e.g., as shown in SEQ ID NO: 30).

[0102] 86. The composition can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, in vitro, topically, etc., including topical intranasal administration or administration by inhalation. As used herein, "topical intranasal administration" means delivery of the composition to the nose and nasal passages through one or both of the two nostrils, and can include delivery by a spray mechanism or a drop mechanism, or by atomization of a nucleic acid or a vehicle. Administration of the composition by inhalation can be nasal or oral by delivery using a spray or drop mechanism. It can also be delivered directly to any area of ​​the respiratory system (e.g., lungs) via intubation. The exact amount of the composition required will vary from subject to subject, depending on the type, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the specific nucleic acid or vehicle used, its mode of administration, etc. Therefore, it is impossible to specify an exact amount for each composition. However, given the teachings herein, a person of ordinary skill in the art can determine the appropriate amount using only routine experiments.

[0103] 87. If used, parenteral compositions are usually characterized by injection. Injections can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for dissolving suspensions in liquids prior to injection, or as emulsions. Recent improvements in parenteral administration methods involve the use of slow-release or sustained-release systems to maintain a constant dose. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated herein by reference.

[0104] 88. The material may be in solution, suspension (eg, incorporated into microparticles, liposomes or cells). These may be targeted to specific cell types via antibodies, receptors or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter et al., Bioconjugate Chem, 2:447-451, (1991); Bagshawe, KD, Br. J. Cancer, 60:275-281, (1989); Bagshawe et al., Br. J. Cancer, 58:700-703, (1988); Senter et al., Bioconjugate Chem., 4:3-9, (1993); Battelli et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler et al., Biochem. Pharmacol, 42:2062-2065, (1991)). Carriers such as "stealth" and other antibody-conjugated liposomes (including lipid-mediated drugs targeting colon cancer), receptor-mediated DNA targeting by cell-specific ligands, lymphocyte-directed tumor targeting, and highly specific therapeutic retroviral targeting of mouse glioma cells in vivo. The following references are examples of using this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49: 6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104: 179-187, (1992)). In general, receptors involve constitutive or ligand-induced endocytosis pathways. These receptors are aggregated in clathrin-coated pits, enter cells via clathrin-coated vesicles, pass through acidified endosomes where the receptors are sorted, and then recirculate to the cell surface, store intracellularly, or degrade in lysosomes. The internalization pathway has multiple functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligands, and regulation of receptor levels. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, ligand type, ligand valency, and ligand concentration. The molecular and cellular mechanisms of receptor-mediated endocytosis are reviewed (Brown and Greene, DNA and Cell Biology, 10:6, 399-409 (1991)).

[0105] a) Pharmaceutically acceptable carrier

[0106] 89. Compositions comprising antibodies may be used therapeutically in combination with a pharmaceutically acceptable carrier.

[0107] 90. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th edition), edited by A. R. Gennaro, Mack Publishing Company, Easton, PA, 1995. Typically, an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to make the formulation isotonic. Examples of pharmaceutically acceptable carriers include, but are not limited to, saline, Ringer's solution, and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Other carriers include sustained release formulations, such as semipermeable solid hydrophobic polymer matrices containing the antibody, the matrix being in the form of a molded article, such as a film, liposome, or microparticle. It will be apparent to those skilled in the art that certain carriers may be more preferred, depending, for example, on the route of administration and the concentration of the composition administered.

[0108] 91. Pharmaceutical carriers are known to those skilled in the art. These pharmaceutical carriers will most typically be standard carriers for administering drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The composition can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

[0109] 92. In addition to the selected molecule, the pharmaceutical composition may also contain carriers, thickeners, diluents, buffers, preservatives, surfactants, etc. The pharmaceutical composition may also contain one or more active ingredients, such as antimicrobial agents, anti-inflammatory drugs, anesthetics, etc.

[0110] 93. The pharmaceutical compositions can be administered in a variety of ways, depending on whether local or systemic treatment is desired, and on the area to be treated. Administration can be topical (including ocularly, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, such as by intravenous infusion, subcutaneous, intraperitoneal, or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavitary, or transdermally.

[0111] 94. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol / aqueous solutions, emulsions or suspensions including saline and buffered media. Parenteral carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution or fixed oils. Intravenous carriers include fluid and nutritional supplements, electrolyte supplements (such as those based on Ringer's dextrose) and the like. Preservatives and other additives may also be present, such as, for example, antimicrobial agents, antioxidants, chelating agents and inert gases, etc.

[0112] 95. Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

[0113] 96. Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be required.

[0114] 97. Some of the compositions may potentially be administered as pharmaceutically acceptable acid or base addition salts formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, tri-, and arylamines, and substituted ethanolamines.

[0115] b) Therapeutic use

[0116] 98. The effective dose and schedule for administering the composition can be determined empirically, and such determination is within the technical scope of the art. The dose for administering the composition is a range large enough to produce the desired effect that the disorder symptoms are affected. The dose should not be large enough to cause adverse side effects, such as undesirable cross-reactions, allergic reactions, etc. In general, the dose will vary with the patient's age, condition, sex and degree of disease, route of administration, or whether other drugs are included in the regimen, and can be determined by a person skilled in the art. In the case of any contraindications, the dose can be adjusted by an individual physician. The dose can vary, and one or more doses can be given daily over one or more days. For a given class of drug products, guidance on appropriate doses can be found in the literature. For example, guidance on the selection of appropriate dosages of antibodies can be found in the literature on the therapeutic use of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., ed., Noges Publications, Park Ridge, NJ, 1985, Chapter 22, pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., ed., Raven Press, New York, 1977, pp. 365-389. Depending on the above factors, a typical daily dosage of an antibody used alone can range from about 1 μg / kg to up to 100 mg / kg body weight or more per day.

[0117] 99. The synthetic PD-1 peptides, chimeras and antibodies disclosed herein that inhibit the interaction of PD-1 and PD-L1 are administered prophylactically to patients or subjects at risk of developing cancer, autoimmune diseases or Alzheimer's disease, or are administered therapeutically (i.e., after disease diagnosis or symptom onset) to treat cancer, autoimmune diseases or Alzheimer's disease.

[0118] 100. Other molecules or antibodies that interact with PD-1 or PD-L1 and inhibit PD-1 / PD-L1 interaction (e.g., pembrolizumab and nivolumab) can be used in combination with the disclosed synthetic PD-1 peptides, chimeric PD-1 peptides, or anti-PD-1 antibodies to treat cancer, autoimmune diseases, or Alzheimer's disease in a subject.

[0119] 4. Antibody 1

[0120] (1) Overview of antibodies

[0121] 101. The term "antibody" is used in a broad sense herein and includes both polyclonal antibodies and monoclonal antibodies. In addition to complete immunoglobulin molecules, the term "antibody" also includes fragments or polymers of those immunoglobulin molecules, as well as human or humanized forms of immunoglobulin molecules or fragments thereof, as long as they are selected for their ability to interact with PD-1, so as to inhibit the interaction between PD-1 and PD-L1. Also disclosed are antibodies that bind to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and / or SEQ ID NO: 19 that are involved in the interaction between PD-1 and PD-L1. The desired activity of these antibodies can be tested using the in vitro assays described herein or by similar methods, and then tested for their in vivo therapeutic and / or preventive activity according to known clinical test methods. There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into subtypes (isotypes), such as IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. Those skilled in the art will recognize comparable mouse classes. The heavy chain constant domains corresponding to the different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively.

[0122] 102. As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., each antibody within the population is identical except for possible naturally occurring mutations that may be present in a small subset of antibody molecules. The monoclonal antibodies herein specifically include "chimeric" antibodies and fragments of such antibodies (as long as they exhibit the desired antagonistic activity), in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass.

[0123] 103. The disclosed monoclonal antibodies can be prepared using any process for producing monoclonal antibodies. For example, the disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In the hybridoma method, mice or other suitable host animals are usually immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.

[0124] 104. Monoclonal antibodies can also be prepared by recombinant DNA methods. DNA encoding the disclosed monoclonal antibodies can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of mouse antibodies). Phage display technology can also be used to generate and screen libraries of antibodies or active antibody fragments, for example, as described in U.S. Pat. No. 5,804,440 to Burton et al. and U.S. Pat. No. 6,096,441 to Barbas et al.

[0125] 105. In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce antibody fragments thereof, particularly Fab fragments, can be accomplished using conventional techniques known in the art. For example, papain can be used for digestion. Examples of papain digestion are described in WO 94 / 29348, published on December 22, 1994, and in U.S. Patent No. 4,342,566. Papain digestion of antibodies generally produces two identical antigen-binding fragments (called Fab fragments, each with a single antigen-binding site) and a residual Fc fragment. Pepsin treatment produces a fragment with two antigen-binding sites and still capable of cross-linking antigens.

[0126] 106. As used herein, the term "antibody or fragment thereof" encompasses chimeric antibodies and hybrid antibodies with dual or multiple antigen or epitope specificity, as well as fragments such as F(ab')2, Fab', Fab, Fv, sFv, etc. (including hybrid fragments). Thus, antibody fragments that retain the ability to bind to the specific antigen of the antibody are provided. For example, antibody fragments that retain PD-1 binding activity or bind to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and / or SEQ ID NO: 19 are included within the meaning of the term "antibody or fragment thereof". Such antibodies and fragments can be prepared by techniques known in the art and can be screened for specificity and activity according to the methods shown in the Examples and the general methods for producing antibodies and screening them for specificity and activity (see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, (1988)).

[0127] 107. The meaning of "antibody or fragment thereof" also includes conjugates of antibody fragments and antigen binding proteins (single-chain antibodies).

[0128] 108. Whether or not connected to other sequences, fragments may also include insertion, deletion, substitution or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the antibody or antibody fragment is not significantly changed or impaired compared to the unmodified antibody or antibody fragment. These modifications may provide some additional properties, such as being able to remove / add disulfide bonds of amino acids, increase their biological lifespan, change their secretion characteristics, etc. In any case, the antibody or antibody fragment must have biological activity, such as specific binding to its cognate antigen. The functional region or active region of the antibody or antibody fragment may be identified by mutagenizing specific regions of the protein, then expressing and testing the expressed polypeptide. Such methods are obvious to those skilled in the art and may include site-specific mutagenesis of nucleic acids encoding antibodies or antibody fragments. (Zoller, MJ, Curr. Opin. Biotechnol., 3: 348-354, 1992).

[0129] 109. As used herein, the term "antibody" may also refer to a human antibody and / or a humanized antibody. Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans and therefore may produce an undesirable immune response when administered to humans. Therefore, the use of human or humanized antibodies in the methods described is used to reduce the chance that an antibody administered to a human will elicit an undesirable immune response.

[0130] (2) Human Antibodies

[0131] 110. Any technology can be used to prepare the disclosed human antibodies. The disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic mutant mice that can respond to immunization and produce a complete human antibody repertoire have been described (see, for example, Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90: 2551-255 (1993); Jakobovits et al., Nature, 362: 255-258 (1993); Bruggermann et al., Year in Immunol., 7: 33 (1993)). Specifically, homozygous deletion of the antibody heavy chain joining region (J (H)) gene in these chimeric and germline mutant mice causes complete inhibition of endogenous antibody production, and successful transfer of human germline antibody gene arrays into such germline mutant mice results in the production of human antibodies after antigen challenge. Antibodies with desired activity are selected using the Env-CD4 co-receptor complex as described herein.

[0132] (3) Humanized Antibodies

[0133] 111. Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Therefore, a humanized form of a non-human antibody (or its fragment) is a chimeric antibody or antibody chain (or its fragment, such as sFv, Fv, Fab, Fab', F(ab')2 or other antigen-binding portion of an antibody) comprising a portion of the antigen-binding site of a non-human (donor) antibody integrated into a human (acceptor) antibody framework.

[0134] 112. In order to generate humanized antibodies, the residues of one or more complementary determining regions (CDR) of the receptor (human) antibody molecule are replaced with the residues of one or more CDRs of the donor (non-human) antibody molecule known to have the desired antigen binding properties (e.g., a certain level of specificity and affinity to the target antigen). In some cases, the Fv framework (FR) residues of human antibodies are replaced with corresponding non-human residues. Humanized antibodies may also include residues that are neither found in the receptor antibody nor in the CDR or framework sequences imported. Usually, humanized antibodies have one or more amino acid residues introduced from non-human sources. In fact, humanized antibodies are usually human antibodies, in which some CDR residues and possible FR residues are replaced by residues from similar sites in rodent antibodies. Humanized antibodies generally include at least a portion of an antibody constant region (Fc) (usually an antibody constant region of a human antibody).

[0135] (4) Administration of Antibodies

[0136] 113. Administration of antibodies may be performed as disclosed herein. There are also nucleic acid methods for antibody delivery. Broadly neutralizing anti-PD1 antibodies and antibody fragments (including any antibodies that bind to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and / or SEQ ID NO: 19) may also be administered to a patient or subject as a nucleic acid preparation (e.g., DNA or RNA) encoding the antibody or antibody fragment, so that the patient's or subject's own cells absorb the nucleic acid and produce and secrete the encoded antibody or antibody fragment. For example, delivery of nucleic acids may be in any manner as disclosed herein.

[0137] C. Methods of treating diseases

[0138] 114. It is understood and contemplated herein that the disclosed compositions, synthetic PD-1 peptides and chimeric PD-1 peptides can be used to treat any disease in which immunosuppression and prevention of programmed cell death is beneficial to the disease, such as Alzheimer's disease, autoimmune diseases, or any disease in which uncontrolled cell proliferation occurs, such as cancer.

[0139] 115. A non-limiting list of different types of autoimmune diseases that can be treated using the chimeric or synthetic peptides or pharmaceutical compositions disclosed herein include, but are not limited to, psoriasis, alopecia areata, primary biliary cirrhosis, autoimmune polyendocrine syndrome, diabetes mellitus type 1, autoimmune thyroiditis, systemic lupus erythematosus, multiple sclerosis, Guillain-Barré syndrome, Graves' disease, Sjögren's syndrome, ulcerative colitis, autoimmune hemolytic anemia, pernicious anemia, psoriatic arthritis, rheumatoid arthritis, relapsing polychondritis, myasthenia gravis, acute disseminated encephalomyelitis, and granulomatous polyangiitis.

[0140] 116. A non-limiting list of different types of cancer that can be treated using the chimeric peptides or synthetic peptides or pharmaceutical compositions disclosed herein includes, but is not limited to, lymphoma (Hodgkin and non-Hodgkin), leukemia, carcinoma, solid tissue cancer, squamous cell carcinoma, adenocarcinoma, sarcoma, glioma, high-grade glioma, blastoma, neuroblastoma, plasmacytoma, histiocytoma, melanoma, adenoma, hypoxic tumors, myeloma, AIDS-related lymphoma or sarcoma, metastatic cancer, or general cancer.

[0141] 117. A representative but non-limiting list of cancers that the disclosed compositions, chimeric peptides and synthetic peptides can be used to treat is as follows: lymphoma, B-cell lymphoma, T-cell lymphoma, mycosis fungoides, Hodgkin's disease, myeloid leukemia, bladder cancer, brain cancer, cancer of the nervous system, head and neck cancer, squamous cell carcinoma of the head and neck, kidney cancer, lung cancer such as small cell lung cancer and non-small cell lung cancer, neuroblastoma / glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinoma of the oral cavity, pharynx, larynx and lung, colon cancer, cervical cancer, squamous cell carcinoma of the cervix, breast cancer and epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, squamous cell carcinoma of the esophagus, squamous cell carcinoma of the head and neck, colorectal cancer, hematopoietic cancer; testicular cancer; colon and rectal cancer, prostate cancer, ipilimumab-refractory melanoma or pancreatic cancer.

[0142] 118. Thus, in one aspect, disclosed herein is a method of treating cancer, Alzheimer's disease, or an autoimmune disease in a subject, the method comprising administering to the subject a PD-1 synthetic peptide, wherein the PD-1 synthetic peptide comprises one or more of the sequences shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. It is understood and contemplated herein that these synthetic peptides may be acetylated, amidated, and / or D enantiomers. Thus, in one aspect, disclosed herein is a method of treating cancer, Alzheimer's disease, or an autoimmune disease in a subject, the method comprising administering to the subject a PD-1 synthetic peptide, wherein the PD-1 synthetic peptide comprises the D enantiomer and / or the reverse-flipped form of the D enantiomer of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:18, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11, as shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, respectively.

[0143] 119. In one aspect, it is understood that the disclosed compositions can be used in combination with other treatments to treat a given disease or condition. For example, in one aspect, disclosed herein is a method of treating cancer, comprising administering a PD-1 peptide, a PD-1 synthetic peptide, or a PD-1 chimeric peptide to a subject; wherein the disease or condition is breast cancer, and wherein the method further comprises administering to the subject one or more HER-2 B cell epitopes (e.g., one or more of the HER-2 peptides as shown in SEQ ID NO: 27 or 29 or the chimeric MVF-HER-2 peptides as shown in SEQ ID NO: 28 or 30) and / or one or more anti-HER-2 antibodies. It is understood that in the case of administering a HER-2 B cell epitope or an anti-HER-2 antibody to a subject, the administration can be as a separate simultaneous administration, the HER-2 B cell epitope or the anti-HER-2 antibody being administered first, the HER-2 B cell epitope or the anti-HER-2 antibody being administered subsequently, or the HER-2 B cell epitope or the anti-HER-2 antibody being a component in the same pharmaceutical formulation as the PD-1 peptide, the PD-1 synthetic peptide, or the PD-1 chimeric peptide. For example, a method of treating breast cancer may include administering to a subject a pharmaceutical composition comprising one or more of the PD-1 peptides set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5; a chimeric PD-1 peptide set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11; and / or a reverse-flip PD-1 peptide set forth in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19; the method further comprising administering to the subject one or more HER-2 B cell epitopes HER-2 (266-296) set forth in SEQ ID NO:27 and / or HER-2 (597-626) set forth in SEQ ID NO:29 and / or a chimeric epitope MVF-HER-2 (266-296) peptide (e.g., ... NO:28) and MVF-HER-2(597-626) peptide (eg, as shown in SEQ ID NO:30).Therefore, in one aspect, disclosed herein is a method for treating breast cancer, the method comprising administering to a subject having breast cancer a pharmaceutical composition comprising MVF-PD1 (92-110) as shown in SEQ ID NO: 11; MVF-HER-2 (266-296) peptide (e.g., as shown in SEQ ID NO: 28) and MVF-HER-2 (597-626) peptide (e.g., as shown in SEQ ID NO: 30).

[0144] 120. It is also understood and contemplated herein that synthetic peptides used to treat cancer, autoimmune diseases, or Alzheimer's disease may be components of chimeric peptides. Thus, in one aspect, disclosed herein are methods of treating cancer, Alzheimer's disease, or autoimmune diseases in a subject, the method comprising administering to the subject a PD-1 chimeric peptide, wherein the chimeric peptide comprises one or more PD-1 B cell epitopes, a helper T cell (Th) epitope, and a linker that connects the PD-1 B cell epitope to the Th epitope, wherein the one or more PD-1 B cell epitopes are selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15. It is also understood and contemplated herein that the synthetic PD-1 peptide (i.e., PD-1 B cell epitope) used in the chimeric peptide may be acetylated, amidated, and / or D enantiomer. In one aspect, for example, disclosed herein is a method of treating cancer, Alzheimer's disease, or an autoimmune disease in a subject, the method comprising administering to the subject a PD-1 chimeric peptide, wherein the chimeric peptide comprises SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 19.

[0145] D. Examples

[0146] 121. The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to prepare and evaluate the compounds, compositions, articles, devices and / or methods claimed herein, and are intended to be exemplary only and not intended to limit the present disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but certain errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, temperature is ° C. or is ambient temperature, and pressure is at or near atmospheric pressure.

[0147] 1. Example 1: Selection, design and modeling of peptide epitopes of PD-1

[0148] 122. Using the six correlations of antigenicity reviewed by Kaumaya et al. TM,5x.com) computer-assisted analysis was performed to complete the selection of candidate B-cell epitopes expressed on the PD-1 surface: (a) chain flexibility and mobility profiles of individual sequences were calculated according to Karplus and Schultz; (b) hydropathicity profiles were generated within a seven-residue span setting and then smoothed with a three-residue span using the Kyte and Doolittle scaling; (c) hydropathicity profiles within a six-residue window were generated using the procedure of Hopp and Woods. profile); (d) analysis of the exposure of the amino acid residues to water by the solvent exposure algorithm of Rose et al. (1.4A probe); (e) calculation of the protrusion index by the method of Thornton et al., which predicts the portion of the protein that is solvent accessible and protrudes into the solvent; (f) determination of the probability that a five-residue sequence is antigenic by the method of Welling et al.; sequences are given a score of 1 to 6 based on their corresponding index values ​​and ranked: the highest ranked sequence has the highest individual score for the analysis examined (6 / 6), and the next candidate has the next highest score (5 / 6), etc. The best scoring epitopes are further ranked by correlation with their secondary structural properties; for example, amphipathic α-helical sequences or β-turn loop regions are preferred over random coil segments. Computer programs by Chou and Fasman and Novotny et al. are used to predict secondary structure (α-helix, β-strand / sheet, β-turn / loop, random coil) and α-helical amphipathic moment. Finally, individual amino acid sequences are considered. Electrostatic ion pairs and helical dipole interactions (e.g., hydrophobic / hydrophilic balance) in helical segments were also considered. The sequences that obtained the highest scores are shown in Table 4. Using this approach, four of the twelve highest scoring B cell epitope sequences for human PD-1 were prioritized. Combined with information from the PD-1:PDL1 (20) crystal structure, amino acids 32-50, 45-64, 73-90, and 92-110 were selected for evaluation. The structures of human PD-1 (PDB 3RRQ) and human PD-L1 (PDB 3BIS, 3FN3, 4Z18, 5C3T) have been determined, but these structures do not subsequently consider the significant plasticity within human PD-1 after complex formation, which has only recently been demonstrated by the structure of the intact human PD-1 / PD-L1 complex (20). Although the above structures provide a complete description of the interaction, the flat surface of the protein-protein interface still complicates drug design efforts if there is no structural information about small molecule inhibitors complexed with either PD-1 or PD-L1 to guide further rational drug development. The crystal structure confirms that the receptor-ligand interaction is mediated in its main part by residues of the COCFG chain in both PD-1 and PDL1 (Figure 1). Protein-protein contacts involve hydrophobic interactions and polar interactions, and buried The total surface area of ​​2. Interactions are established around the central hydrophobic core contributed by the two partners and composed of non-polar residues in the PD-1 front sheet (Val64, Ile126, Leu128, Ala132, Ile134) and non-polar residues in the PD-L1 front sheet (LIle54, LTyr56, LMet115, LAla121, LTyr123), including characteristic alkyl-p interactions of the side chains of Ile134 and LTyr123. This hydrophobic region leads to the solvent on the quasi-antigen binding site and is adjacent to a buried region of mixed polar / non-polar interactions on the opposite side of the molecule. These two regions are surrounded by a peripheral network of polar residues (safe on the CDR loop side), providing additional hydrogen bond-mediated interactions between the receptor and the ligand. The structure shows that hPD-1 (comprising residues 16–127 of the mature polypeptide) consists of a two-layer sandwich structure with the topology of the IgSF domain (i.e., two β-sheets (GFCC and ABED) stabilized by disulfide bonds (Cys34–Cys103)). Figure 2A , Figure 2B and Figure 2C Modeling of the PD-1 peptide according to the conformational epitope is shown.

[0149] Table 4: Predicted B cell epitopes of human PD-1

[0150] Residue sequence Secondary structure 32-50 VLNWYRMSPSNQTDKLAAF(SEQ ID NO:2) Antiparallel β-sheets / loops 45-64 KLAAFPEDRSQPGQDCRFR(SEQ ID NO:3) 73-90 DFHMSVVRARRNDSGTYL(SEQ ID NO:4) 92-110 GAISLAPKAQIKESLRAEL(SEQ ID NO:5)

[0151] Figure 2A , Figure 2B and Figure 2C Modeling of the PD-1 peptide according to the conformational epitope is shown.

[0152] 2. Example 2: Synthesis, purification and characterization of PD-1 peptide and MVF-PD-1 peptide

[0153] 123. Peptide synthesis was performed using Fmoc / Boc chemistry using a 9600 Milligen / Biosearch solid phase peptide synthesizer (Millipore, Bedford, MA). Clear amide resin (0.50 mmol / gm) (Peptide International, Louisville, KY) and Fmoc-protected amino acids (P3 BioSystems, Louisville, KY) were used for the synthesis of all peptides. For chimeric peptides, B cell epitopes were synthesized colinearly with promiscuous Th MVF (residues 288–302) epitopes using regioselective side chain protection and GPSL linkers. Some of the B cell epitopes were acetylated using acetylimidazole in DMF (Sigma-Aldrich St.Louis, MO). The peptides were reacted overnight and then washed with DMF before cleavage. Peptides were cleaved using reagent R (trifluoroacetic acid: TFA: Thiansole: EDT: anisole, 90:5:3:2) (Sigma-Aldrich, St.Louis, MO). Crude peptides were purified by reverse phase HPLC using a C-4 vydac column in a gradient system of water / acetonitrile (0.1% trifluoroacetic acid) on a Waters system. At the end of purification, pure fractions were then analyzed in analytical HPLC, and the fractions of interest were combined and lyophilized in 10% acetic acid solution. The final purified peptides listed in Table 5 were then identified using mass spectrometry (Campus Chemical Instrumentation Center, The Ohio State University, Columbus, OH).

[0154] Table 5: Peptide sequences of PD-1

[0155]

[0156] 3. Example 3: Determination of binding specificity of PD-1 peptides by BIACORE

[0157] a) Biacore immobilization

[0158] 124. To test the activity of all selected peptides, their binding affinity to the extracellular domain of human PD-L1 (hPD-L1) was measured using surface plasmon resonance (SPR) spectroscopy (Biacore T200 at 258°C). Recombinant hPD-L1 extracellular domain was immobilized on the gold surface of a CM5 sensor chip by direct amine coupling. To confirm that the immobilized hPD-L1 extracellular domain was functional, its affinity to the extracellular domain of recombinant human PD-1 (hPD-1) was examined.

[0159] 125. In order to obtain the theoretical maximum response after peptide binding, the calculated immobilization amounts of rhPD-L1, nivolumab and human IgG were 9790RU, 14286RU and 14286RU, respectively. After activation with EDC / NHS, 20 μg / ml of rhPD-L1 in 10 mM NaAc pH 5.5, nivolumab in 10 mM HEPES, pH 7.5 and human IgG in 10 mM HEPES, pH 7.0 were injected onto the chip at 10 μl / min for 7 min. rhPD-L1( Figure 3A )、Nivolumab( Figure 3B ), human IgG( Figure 3C ) were 2345RU, 12264RU and 11651RU, respectively.

[0160] b) Specificity of the rhPD-1 and nivolumab binding assay

[0161] To verify the prepared sensor chip, 1 μM (17.3 μg / ml) rhPD-1 was injected into the chip at 10 μl / min within 3 min ( Figure 3D ). 1 μM BSA was used as a negative control. The chip was regenerated with 10 mM glycine hydrochloride (pH 2.5) ( Figure 3E ). It can be seen that nivolumab generated a strong response signal (3740RU) after rhPD-1 injection, and rhPD-L1 caused a weak signal (461RU), while human IgG did not show any binding signal. BSA did not cause any binding, indicating that the binding of PD-1 to nivolumab and rhPD-L1 is specific.

[0162] c) Determination of the specificity of PD-1 peptide binding to rPD-L1 and nivolumab by Biacore

[0163] 127. For each run, 1 μM of each PD-1 peptide was injected onto the chip at 10 μl / min for 1 min, followed by 1 min of dissociation and subsequent 1 min of regeneration with 10 mM glycine HCl, pH 2.5. Figure 4A MVF-PD-1(45-64), MVF-PD-1(73-90), MVF-PD-1(92-110) were shown to bind to immobilized rhPD-L1, producing approximately 110 RU. In contrast, MVF-PD-1(32-50) exhibited very weak binding (11 RU) similar to the negative control MVF-HER-2(266-296) (20 RU). The same three positive MVF-peptides showed stronger binding to nivolumab, at 1030 RU, 1000 RU, 970 RU ( Figure 4B). Likewise, MVF-PD-1(32-50) showed negligible binding capacity (20RU), indicating that this sequence does not represent a viable epitope. It was concluded that MVF-PD-1(45-64, 73-90, and 92-110) were able to recognize both rhPD-L1 and nivolumab, whereas MVF-PD-1(31-49) was not. In addition, the acetylated peptides also bound to rhPD-L1 and nivolumab, although more weakly than the chimeric MVF peptide ( FIG. 4C to FIG. 4D The free peptide also bound to both PD-L1 and nivolumab, with PD-1(73-90) showing much stronger binding to rhPD-L1 and nivolumab compared to PD-1(45-64) and PD-1(92-110) ( Figure 4E , Figure 4F ). PD-1(45-64) is the second strongest binder. Therefore, the binding efficiency of the free peptides can be ranked as follows: 73-90>46-64>92-110. Based on these binding studies, it can be concluded that the PD-1 peptides 46-64, 73-90 and 92-110 can recognize rPD-L1 and can act as small peptide inhibitors of the PD-1:PD-L1 interaction.

[0164] 4. Example 4: Immunogenicity test of PD-1 peptide in rabbits

[0165] a) MVF-PD-1 peptide elicits high titer anti-peptide antibodies.

[0166] 128. These four PD-1 sequences were synthesized as chimeric constructs with promiscuous helper T cell epitopes derived from measles virus fusion protein (MVF, amino acids 288-302). The vaccine construct 1 mg peptide was emulsified in Montanide ISA 720 (Seppic, Paris, France) and nor-MDP adjuvant (N-acetylglucosamine-3-yl-acetyl L-alanyl-D-isoglutamine) and used to immunize New Zealand white rabbits, which were purchased from Charles River Laboratories, Wilmington, Massachusetts and housed in the Ohio State University's University Laboratory Animal Resources (ULAR) facility. Rabbits were vaccinated three times in total at three-week intervals. Animals were bled weekly and sacrificed at nine weeks, and terminal bleeding was performed by cardiac puncture at the last test bleeding. All experiments were performed in accordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals, approved by the Ohio State University Institutional Animals Care and Use Committee, and detailed in the accepted protocol. Peptide vaccine antibodies were purified by affinity chromatography using protein A / G columns, and concentrations were measured by Coomassie protein assay.

[0167] 129. All four epitopes elicited high titer antibodies against the immunization vaccine >250,000, Figure 5A The terminal bleed antibody also recognized the recombinant human PD-1 protein as well as the immune peptide MVF-PD-1, acetylated peptide and free peptide. Figure 5B .

[0168] b) (ii) Homology between human and mouse PD-1 sequences for selected epitopes.

[0169] 130. There is 65% overall homology between human and mouse PD-1 sequences. The selected epitopes showed 67%-74% homology between human and mouse sequences. Therefore, it is important to see if the selected human epitopes can bind to mouse PD-1 to validate the mouse studies.

[0170] c) (iii) α-hPD-1 rabbit polyclonal antibody binds to mouse PD-1

[0171] 131. To determine whether the α-hPD-1 rabbit polyclonal antibody recognizes mouse PD-1, spleen cells from naive myelin basic protein (MBP)-specific TCR transgenic mice were activated with MBP Ac1-11 for 72 h. PD-1 expression was analyzed by flow cytometry. Figure 6 As shown in , all four polyclonal α-hPD-1 antibodies bound to mouse PD-1, validating the use of human PD-1 in tumor mouse studies.

[0172] d) (iv) Regulation of T cell proliferation by α-hu PD-1 antibody

[0173] 132. Antigen-specific T cell proliferation reflects the important effector function of effector T cells. To determine whether these four α-huPD-1 antibodies can alter T effector function by activating or inhibiting the PD-1 signaling pathway, a CFSE-based proliferation assay ( Figure 7 ). Briefly, splenocytes taken from naive MBP-specific TCR transgenic mice were labeled with CFSE and activated with MBP Ac1-11 for 4 days in the presence of 50 mg / ml α-huPD-1 antibody or control rabbit IgG. CFSE expression was analyzed by flow cytometry. The data showed that 81% of CD4 T cells treated with α-hPD-1-92-110 were highly proliferative, compared to only 70% of T cells in the control IgG-treated group, indicating that α-hPD-1-92-110 blocked PD-1 / PD-L1 interactions and caused enhanced T effector function represented by increased antigen-specific proliferation of myelin-specific CD4 T cells. In contrast, T cells treated with α-hPD-1 (45-64) or α-hPD-1 (73-90) showed decreased proliferation, indicating that they activated PD-1 signaling and inhibited the effector function of myelin-specific CD4 T cells. Additionally, α-hPD-1(32-50) had no effect on T effector function, as cells treated with α-huPD-1(32-50) proliferated to the same level as cells treated with control IgG. Together, these data suggest that α-hPD-1(92-110) enhances T effector function and has therapeutic potential in inhibiting tumor growth in vivo. The 45-64 and 73-90 epitopes may be used as targets for autoimmune diseases due to their properties of activating PD-1 signaling.

[0174] 5. Example 5: Immunogenicity testing of PD-1 peptides and tumor attack experiments in immune-competent mice

[0175] a) Mouse vaccination and tumor challenge protocol.

[0176] 133.6-8 week old immune competent Balb / c mice were purchased from Charles River Laboratories, Wilmington, Massachusetts and housed in the Ohio State University's University Laboratory Animal Resources (ULAR) facility. The animals were anesthetized with isoflurane before cell injection and sacrifice. Pre-immune serum samples were collected from mice and then 100 μg of peptide emulsified in Montanide ISA 720 (Seppic, Paris, France) and nor-MDP adjuvant (N-acetylglucosamine-3-yl-acetyl L-alanyl-D-isoglutamine) was used to immunize these mice. Mice received booster immunizations 3 weeks and 6 weeks after the first immunization. Several test serum samples were collected from mice ( Figure 8 ).

[0177] b) Tumor attack :

[0178] 134. Ten days after the second booster immunization, 1×10 5 Mice were inoculated with 1×10 CT26 mouse colon cancer tumor cells. Tumor growth was monitored three times a week, and serum samples were collected weekly and after the animals were sacrificed. On day 0, control mice were implanted subcutaneously with 1×10 5 CT26 tumor cells and make them accept antibodies. These animals received 150μg of anti-mouse antibody injections for PD-1. Mice were monitored twice a week and the formation of palpable tumors was scored, and then the mice were killed when the tumors were necrotic or exceeded a predetermined size of 2,000mm3. Tumor diameter was measured twice a week. Tumor size was calculated according to the following formula: V = [(length × width 2) / 2]. Tumor volume (in cubic millimeters) was measured with a caliper and calculated using the following formula: A × B2 × 0.5, where A is the maximum diameter and B is the minimum diameter. All experiments were performed in accordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals, and have been approved by the Ohio State University Institutional Animals Care and Use Committee and are detailed in the accepted protocol.

[0179] c) Immunogenicity of PD-1 vaccine constructs in mice .

[0180] 135. All individual mice generated potent antibody responses to all 4 vaccines. The immune responses to pooled sera against the vaccine constructs were monitored at various intervals (2Y+1, 2Y+3, 3Y+1, 3Y+2, 3Y+3). Fig. 9 and Table 6).

[0181] Table 6: Resistance to recombinant hu in rabbits and mice Antigenicity of PD-1 protein in terminal bleeds

[0182]

[0183] Final mouse and rabbit sera were tested for reactivity to recombinant huPD1 protein (600 ng / well). Sera were tested at 1:100 and 1:200 dilutions. ABTS was used as the substrate in the assay. Samples were read and scored at 415 λ.

[0184] d) Detection of immune cells in mouse tissues

[0185] 136. Tumors and tumor draining lymph nodes were collected for subsequent FACS analysis to study immune responses in mice. Cell suspensions were prepared from tissues by mechanical dissociation or by enzymatic digestion. The stained cells were analyzed using an LSR II flow cytometer (BD Biosciences) equipped with 3 excitation lasers at wavelengths of 405, 488, and 633 nm. CD8+T cells and CD4+CD25+T cells taken from tumor leukocytes were purified on MACS columns or FACSAria.

[0186] e) Immune profiling of T cell responses in treated mice

[0187] 137. Flow cytometry was performed to evaluate the expression of surface markers (CD45, CD3, CD4, CD8 and CD25) and transcription factor FoxP3 in splenocytes and tumor-infiltrating T cells. In brief, the spleen was removed from the mouse and squeezed through a cell strainer, followed by a brief incubation with red blood cell lysis buffer to lyse red blood cells. The cells were then collected, washed and resuspended in staining buffer (1% BSA in PBS). Similarly, tumors were removed from the mouse and squeezed through a cell strainer, followed by a wash with 37% percoll. The tumor cells were then washed with PBS and resuspended in staining buffer. Splenocytes and tumor cells were incubated with mAbs for cell surface markers at 4°C for 30min. After washing twice with staining buffer, the cells were fixed and permeabilized at 4°C for 60min using Cytofix / Cytoperm solution. The cells were stained for FoxP3 at 4°C for 30min. 80,000–100,000 live cell events were acquired on a FACSCanto (BD) and analyzed using FlowJo software (Tree Star, Inc.). In order to distinguish infiltrating cells from tumor cells, tumor cells were first gated on CD45+ cells. CD3+CD4+ and CD3+CD8+ cells were then analyzed. Tregs are represented by CD4+CD25+FoxP3+ cells. As shown in Figure 10A, CD4 and CD8 subsets were at similar levels in the spleen, while groups C, E, and F showed increased Treg populations in the spleen compared to group A (negative control). In tumors, group C had the highest Treg ( Fig. 10B ), indicating that peptide PD1-45-64 vaccination resulted in enhanced Treg development in the tumor microenvironment. Group E had the lowest Treg.

[0188] f) Immunized with PD-1 construct and treated with 1×10 5 Syngeneic Balb / c mice challenged with murine colon cancer CT26 tumor cells Efficacy studies in

[0189] 138. Figure 11A- Fig.11H Separate graphs of tumor growth are shown in mice (5 / group) immunized with each of the four PD-1 constructs A: (PD-1(32-50), B: PD-1(45-64), C: PD-1(73-90) and D: PD-1(92-110), a control peptide (E: irrelevant peptide), and a positive control group (F) treated with an anti-mouse PD-1 monoclonal antibody.

[0190] g) Preliminary statistical analysis of mouse tumor growth data

[0191] 139. To evaluate the performance of the four different vaccine treatments on tumor growth, tumor size was measured periodically in mice and the results were compared to those of positive and negative controls. There were five mice in each treatment group, and each mouse received the assigned MVF-peptide and was then vaccinated with 1e5 CT26 (colon) tumor cells 10 days after the last booster of that treatment. Day 14 was considered the main time point of interest because the researchers felt that waiting until day 19 would give the tumors too much time to grow and thus produce similar sizes at that experimental time point. Tumor size was measured in three ways: LWW (1 / 2*length*width*width) at all time points, LWH (1 / 2*length*width*height) at all time points, and terminal tumor weight at the end of the study. Group C mice treated with MVF-PD-a (45) were sacrificed before day 19 due to the death of one mouse, so comparison of tumor size could only be made on day 14. Tumor size is in mm3 for LWW and LWH and in grams for terminal tumor weight.

[0192] 140. Due to the small sample size in each group and the lack of normality, the exact Wilcoxon rank sum test was used to examine the systematic differences in the distribution of tumor size at 14 and 19 days ( FIG. 12A to FIG. 12D The p values ​​given are for the test comparing the control to the corresponding treatment in that column and are two-sided to account for the possibility that tumor size is systematically larger or smaller between treatment and control. As this is preliminary data, p values ​​were not adjusted for multiple comparisons. Overall, there were only a few significant differences between the distributions of control and treatment.

[0193] Table 7: Comparison of median size of MVF-PD-1 (32-50) and control size

[0194]

[0195] For MVF-PD-a (32), there were no significant differences in tumor size distribution between treatment and either positive or negative controls.

[0196] Table 8: Comparison of median size of MVF-PD-1 (45-64) and control size

[0197]

[0198] For MVF-PD-1(45-64), as previously noted, only data from day 14 could be compared. Here, no significant differences in tumor size distribution were found between this treatment and either control.

[0199] Table 9: Comparison of MVF-PD-1 (73-90) median size with control size

[0200]

[0201] For MVF-PD-1(73-90), there were no significant differences in tumor size distribution between the treatment and either control at Day 14. There was a significantly smaller p-value (<0.1) for LWH at Day 19 when comparing treatment to the positive control, indicating a possible difference in tumor size distribution.

[0202] Table 10: Comparison of MVF-PD-1 (92-110) median size with control size

[0203]

[0204] For MVF-PD-1(92-110), there was also a significantly smaller p-value when comparing this treatment to the positive control using both measures, LWW and LWH. This treatment exhibited a distribution with systematically smaller tumor sizes compared to the positive control.

[0205] 6. Example 6: PD-1 peptide antibodies are inhibitory or activating

[0206] 141. Antigen-specific T cell proliferation reflects the important effector function of effector T cells. In order to determine whether these four α-huPD-1 antibodies can change T effector function by activating or inhibiting the PD-1 signaling pathway, a CFSE-based proliferation assay was performed. In the proliferation assay, splenocytes taken from naive MBP-specific TCR transgenic mice were labeled with CFSE, and these splenocytes were activated with MBP Ac1-11 for 4 days in the presence of 50 mg / ml of α-huPD-1 antibody or control rabbit IgG. CFSE expression was analyzed by flow cytometry ( Figure 13A and Fig. 13B ). The data showed that 81% of α-hPD-1-92-110-treated CD4 T cells were highly proliferative, compared to only 70% of T cells in the control IgG-treated group, indicating that α-hPD-1-92-110 blocked the PD-1 / PD-L1 interaction and caused enhanced T effector function represented by increased antigen-specific proliferation of myelin-specific CD4 T cells. In contrast, T cells treated with α-hPD-1 (45-64) or α-hPD-1 (73-90) showed decreased proliferation, indicating that they activated PD-1 signaling and inhibited the effector function of myelin-specific CD4 T cells. Together, these data suggest that α-hPD-1 (92-110) enhances T effector function and may have therapeutic potential in inhibiting tumor growth in vivo. The 45-64 and 73-90 epitopes can be used as targets for autoimmune diseases due to their properties of activating PD-1 signaling.

[0207] 7. Example 7: Immunization with different PD-1 constructs and 1×10 5 Mouse colon cancer CT26 tumor cells challenge Preliminary screening efficacy study in Balb / c mice

[0208] 142. Immunocompetent Balb / c mice (5 mice / group) aged 6-8 weeks were immunized with 100 μg of peptide emulsified in Montanide ISA 720 (Seppic, Paris, France) and nor-MDP adjuvant (N-acetylglucosamine-3-yl-acetyl-L-alanyl-D-isoglutamine). Mice received booster immunizations at 3 and 6 weeks after tumor challenge: 10 days after the second booster immunization, 1×10 5 Mice were subcutaneously inoculated with 1×10 CT26 mouse colon cancer tumor cells, and tumor growth was monitored three times a week. On day 0, control mice were subcutaneously implanted with 1×10 5 The immune responses to the pooled sera against the vaccine constructs and against the recombinant PD-1 protein were monitored at various intervals (2Y+1, 2Y+3, 3Y+1, 3Y+2, 3Y+3). Fig.14 ) (Table 11). All individual mice generated potent antibody responses to all four vaccines.

[0209] Table 11

[0210]

[0211] Final mouse and rabbit sera were tested for reactivity to recombinant huPD1 protein (600 ng / well). Sera were tested at 1:100 and 1:200 dilutions. ABTS was used as the substrate in this assay. The samples were read and scored.

[0212] 8. Example 8: Validation of the PD-1 (92-110) epitope as a vaccine candidate:

[0213] 143. All vaccinated mice showed high immunogenicity, forming high titer antibodies to the corresponding immunogens. Only mice vaccinated with MVF-PD-1 (92-110) showed significant inhibition of tumor growth on day 14 ( Fig.15 ), indicating that this epitope is a useful inhibitory vaccine. Studies showing that epitopes 45-64 and 73-90 are not inhibitory and therefore enhance tumor growth further validate this conclusion. On the other hand, the mouse PD1 mAb (29F.1A12) as a positive control should have inhibited tumor growth. It was concluded that only the PD-1 (92-110) epitope is the most suitable candidate for a vaccine because this epitope was designed based on its binding properties with nivolumab.

[0214] 9. Example 9: Using 1×10 5 Syngeneic Balb / c mice challenged with mouse colon cancer CT26 / HER-2 tumor cells Efficacy of combined PD-1 and HER-2 vaccine constructs ( Fig.16 plan).

[0215] 144. The rationale for this study was to determine whether the combination of HER-2 vaccine and PD-1 (92-110) vaccine could enhance / increase immunogenicity, enhance anti-tumor responses and provide a synergistic beneficial effect in inhibiting tumor growth in a syngeneic cancer model. Balb / c mice (10 mice / group) were immunized with a combination of MVF-PD-1 (92-110), MVF-HER-2 (266-296) and MVF-HER-2 (597-626) peptide vaccine constructs emulsified with nor-MDP and ISA 720. Animals were boosted twice at 3-week intervals. Antibody titers were determined by ELISA on 200ng / well MVF-peptide.

[0216] Two weeks after the last booster immunization, 1×10 cells of the CT26 / HER-2 tumor cell line were subcutaneously transplanted. 5 tumor cells. 5 Tumor cells attack control mice and treat control mice with anti-PD-1 antibodies (29F.1A12) twice a week for the duration of the experiment. Once the tumor reaches a palpable size, the tumor is measured using a caliper to determine the tumor load. CT-26 / HER-2 tumor-bearing mice were killed 21 days after transplantation. Blood and tissue samples were collected from these mice at the time of killing, and the final weight of the excised tumor mass was obtained. Test 1:100-1:512,000 serum concentration. ABTS is used as a substrate in the assay, and the enzyme reaction is stopped with 0.1% SDS solution after 10 minutes. Titer is defined as the final dilution with an absorbance of>0.200 when read at 415nm. Serum samples 1Y+3, 2Y+1, 2Y+3 and 3Y+2 were collected before CT-26HER-2neu tumor attack. Samples 3Y+3 and 3Y+5 were collected 1 week and 3 weeks after attack, respectively. Potent HER-2 and PD-1 antibody responses were elicited in all vaccinated mice ( Fig.17 ).

[0217] 146. Separate graphs of tumor growth in syngeneic Balb / c mice (10 / group) immunized 3 times at 3-week intervals with PD-1 (92-110) alone or in combination with two Her2 peptide immunogens. An immune control group immunized with an irrelevant peptide was included. CT-26 Her2 neu cancer cells (1×10 5) mice. Control mice were also challenged with CT-26Her2neu cancer cells. Control mice were treated with anti-Ms PD-1 MAb (positive control) or PBS (negative control) by intraperitoneal injection twice a week. The mice were monitored and the formation of palpable tumors was scored, and the tumor size was then measured regularly with a caliper. The animals were sacrificed 21 days after tumor cell transplantation. The error bars are representations of the standard error of the group of mice, and the p values ​​compare the various groups with the triple vaccine mice. The results show that triple vaccination can effectively reduce tumor growth in the Balb / c syngeneic model of colon cancer compared to the PD-1 vaccine or, more importantly, the positive control gold standard: anti-mouse PD-1 monoclonal antibody (29F.1A12). Fig.18 ).

[0218] 147. The data showed that the triple vaccination group MVF-PD-1 (92-110) + MVF-HER-2 (266 + 296) + MVF-HER-2 (597-626) was more effective in preventing tumor growth than the positive control anti-mouse PD-1 Mab (29F.1A12) or vaccination with MVF-PD-1 alone ( Fig.19A and Fig.19B ). Therefore, the strategy of triple vaccination with combined HER-2 and PD-1 peptides is a feasible proposal to exhibit synergy / additivity, ultimately enhancing immunogenicity and inhibiting tumor growth.

[0219] 10. Example 10: PD-1 vaccine is safe and does not show toxicity or autoimmunity

[0220] 148. All vaccinated mice showed no signs of dirtiness, lesions, and lethargy over a 9-week period. Organs (spleen, liver, heart, lung, kidney, and tumor) of Balb / c mice vaccinated with combined peptides (HER-2 and PD-1) were collected from mice and sent to the Comparative Pathology & Mouse. Phenotyping Core facility of the Comprehensive cancer center department of Veterinary Biosciences for analysis (pathologist: Krista M.D. La Perle, Doctor of Veterinary Medicine, ACVP certified). No obvious lesions were found in any organ sent for histological evaluation. No obvious biochemical abnormalities were found. All mice had hepatocyte vacuolization consistent with glycogenosis. Glycogen accumulation in the liver is interpreted as a normal manifestation and will change with the physiological state of the animal. Glycogen accumulation can also be observed as a manifestation of toxicity or when glycogen storage disease occurs.

[0221] 11. Example 11: Combined peptide vaccine significantly increased the CD8 / Treg ratio in tumor infiltrating cells (TIL)

[0222] 149.CD25 + FoxP3 + CD4 regulatory T cells (Treg) are one of the main inhibitory populations in the tumor microenvironment that play an important role in the formation of the immunosuppressive tumor microenvironment (TME). On the other hand, a large number of T cells (especially CD8 T cells) at the tumor site are key elements for the overall survival (OS) of cancer patients. High CD8 / Treg ratios are associated with good prognosis for cancer. Therefore, the CD8 / Treg ratio in TICs of tumor-bearing mice vaccinated with combined peptides or control peptides (described above) was determined. Tumors were removed from four groups of mice (described above) and squeezed through a cell strainer, followed by washing twice with 37% percoll. These cells were incubated with mAbs of cell surface markers (CD45, CD4, CD8, CD25). Cytofix / Cytoperm solution (ebioscience) was then used to fix and permeabilize these cells at 4°C for 60min, followed by staining FoxP3 at 4°C for 30min. 80,000–100,000 live cell events were acquired on a FACSCantoII (BD) and analyzed using FlowJo software (Tree Star, Inc.). To distinguish TILs from tumor cells, these cells were first gated on CD45 + Then analyze CD4 + (Figure 20A) and CD8 + (Figure 20B) Treg cells are composed of CD4 + CD25 + FoxP3 + Cells are represented (Figure 20C). GraphPad software (GraphPad Prism Software, Inc., San Diego, CA, USA) was used for statistical analysis. Group means were calculated and compared using analysis of variance. Compared with the control peptide vaccination group, CD8+ T cells were significantly higher in the combination vaccine group (HER-2 / PD1-92 vaccination group) (Figure 20B). There were no significant differences in CD4 T cells or Treg cells between all groups (Figures 20A and 20B). However, the CD8 / Treg ratio was significantly higher in the combination vaccine group compared with the control peptide vaccination group (Figure 20A). Fig.20D ). Therefore, these data indicate that the CD8 / Treg ratio was increased in the HER-2 / PD-1 vaccinated group compared to the control peptide vaccinated group.

[0223] 12. Example 12: Analysis of tumor infiltrating lymphocytes from peptide-vaccinated mice

[0224] 150. High CD8 / Treg ratio is associated with good prognosis of cancer. In order to determine whether peptide vaccines can increase CD8 / Treg ratio, CD8+, CD4+ and regulatory T cells (FoxP3+CD25+CD4+) tumor infiltrating lymphocytes were analyzed in mice vaccinated with peptide vaccines. Flow cytometry was performed to evaluate the expression of surface markers (CD45, CD4, CD8 and CD25), and the expression of transcription factor FoxP3 was determined by intracellular staining (Figure 21A). In short, tumors were removed from mice and squeezed through a cell strainer, followed by washing twice with 37% percoll. These cells were then resuspended in staining buffer and incubated at 4°C for 30min with mAbs of cell surface markers. After washing twice with staining buffer, Cytofix / Cytoperm solution (ebioscience) was used to fix and permeabilize cells at 4°C for 60min. The cells were then stained for 30min at 4°C for FoxP3. 80,000–100,000 live cell events were acquired on a FACSCanto II (BD) and analyzed using FlowJo software (Tree Star, Inc.). To distinguish infiltrating cells (CD45+) from tumor cells (CD45-), all cells were first gated on CD45+ cells. The percentages of CD4+ and CD8+ cells in the CD45+ tumor-infiltrating population were then analyzed. Tregs were represented by FoxP3+CD25+CD4+ cells. GraphPad software (GraphPad Prism Software, Inc., San Diego, CA, USA) was used for statistical analysis. Group means were calculated and compared using analysis of variance. Fig.21B As shown, CD8+ T cells were significantly higher in the PD-1 peptide or PD-1 / Her-2 vaccination groups (Groups 1 and 2) compared with the control peptide vaccination group (Group 3). However, Treg cells were not significantly different between the PD-1 peptide, PD-1 / Her-2 vaccination groups and the control peptide vaccination group. Together, these data indicate that the CD8 / Treg ratio was increased in the PD-1 peptide or PD-1 / Her-2 vaccination groups compared with the control peptide vaccination group.

[0225] E. References

[0226] Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res. 2005;65(6):591 - 604.

[0227] Allen, S.D., et al., Peptide vaccines of the HER-2 / neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol, 2007. 179(1): p. 472 - 82.

[0228] Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer cell. 2014;25(3):282 - 303. Epub 2014 / 03 / 22.

[0229] Baras, A.S., et al., The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology, 2016. 5(5): p. e1134412.

[0230] Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23(11):2445 - 59. Epub 2005 / 03 / 09.

[0231] Baselga J,Swain SM.Novel anticancer targets:revisiting ERBB2 anddiscovering ERBB3.Nature reviews Cancer.2009;9(7):463-75.Epub 2009 / 06 / 19.

[0232] Baselga J.Targeting tyrosine kinases in cancer:the secondwave.Science.2006;312(5777):1175-8.Epub 2006 / 05 / 27.

[0233] Brahmer JR,Tykodi SS,Chow LQ,Hwu WJ,Topalian SL,Hwu P,Drake CG,Camacho LH,Kauh J,Odunsi K,Pitot HC,Hamid O,Bhatia S,Martins R,Eaton K,ChenS,Salay TM,Alaparthy S,Grosso JF,Korman AJ,Parker SM,Agrawal S,Goldberg SM,Pardoll DM,Gupta A,Wigginton JM.Safety and activity of anti-PD-L1 antibody inpatients with advanced cancer.The New England journal of medicine.2012;366(26):2455-65.

[0234] Chames P,Van Regenmortel M,Weiss E,Baty D.Therapeutic antibodies:successes,limitations and hopes for the future.Br J Pharmacol.2009;157(2):220-33.

[0235] Chou PY,Fasman GD.Prediction of the secondary structure of proteinsfrom their amino acid sequence.Advances in enzymology and related areas ofmolecular biology.1978;47:45-148.

[0236] Cobleigh MA,Langmuir VK,Sledge GW,Miller KD,Haney L,Novotny WF,Reimann JD,Vassel A.A phase I / II dose-escalation trial of bevacizumab inpreviously treated metastatic breast cancer.Seminars in oncology.2003;30(5Suppl 16):117-24.

[0237] Dakappagari NK,Douglas DB,Triozzi PL,Stevens VC,Kaumaya PT.Preventionof mammary tumors with a chimeric HER-2B-cell epitope peptide vaccine.CancerRes.2000;60(14):3782-9.

[0238] Dakappagari NK,Lute KD,Rawale S,Steele JT,Allen SD,Phillips G,ReillyRT,Kaumaya PT.Conformational HER-2 / neu B-cell epitope peptide vaccinedesigned to incorporate two native disulfide bonds enhances tumor cellbinding and antitumor activities.J Biol Chem.2005;280(1):54-63.

[0239] Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003;170(8):4242-53. Epub 2003 / 04 / 12.

[0240] Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, Kaumaya PT. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J Pept Res. 2005;65(2):189-99. Epub 2005 / 02 / 12.

[0241] deLeeuw, R.J., et al., The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res, 2012. 18(11): p. 3022-9.

[0242] Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors;a review. European journal of cancer. 2006;42(18):3127-39. Epub 2006 / 11 / 14.

[0243] Folkman J.Tumor angiogenesis:therapeutic implications.The New Englandjournal of medicine.1971;285(21):1182-6.

[0244] Foy KC,Liu Z,Phillips G,Miller M,Kaumaya PT.Combination treatmentwith HER-2and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.J Biol Chem.2011;286(15):13626-37.Epub 2011 / 02 / 18.

[0245] Foy KC,Miller MJ,Moldovan N,Carson WE,Kaumaya PTP.Combinedvaccination with HER-2peptide followed by therapy with VEGF peptide mimicsexerts effective anti-tumor and anti-angiogenic effects in vitro and invivo.OncoImmunology.2012;1(7):0-1.

[0246] Foy KC,Vicari D,Kaumaya PTP.Therapeutic Peptides Targeting HER-2 / neuand VEGF Signaling Pathways in Breast Cancer.Handbook of Biologically ActivePeptides2013.p.612-6.

[0247] Garrett, J.T., et al., Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2 / neu. J Immunol, 2007. 178(11): p. 7120 - 31.

[0248] Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology(Williston Park). 2006; 20(14 Suppl 10): 21 - 8. Epub 2007 / 03 / 16.

[0249] Hadrup, S., M. Donia, and P. Thor Straten, Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron, 2013. 6(2): p. 123 - 33.

[0250] Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss - Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab(anti - PD - 1) in melanoma. The New England journal of medicine. 2013; 369(2): 134 - 44.

[0251] Harding FA,Stickler MM,Razo J,DuBridge RB.The immunogenicity ofhumanized and fully human antibodies:residual immunogenicity resides in theCDR regions.mAbs.2010;2(3):256-65.

[0252] Hoeben A,Landuyt B,Highley MS,Wildiers H,Van Oosterom AT,DeBruijnEA.Vascular endothelial growth factor and angiogenesis.PharmacolRev.2004;56(4):549-80.

[0253] Hopp TP,Woods KR.Prediction of protein antigenic determinants fromamino acid sequences.Proceedings of the National Academy of Sciences of theUnited States of America.1981;78(6):3824-8.

[0254] Houck KA,Ferrara N,Winer J,Cachianes G,Li B,Leung DW.The vascularendothelial growth factor family:identification of a fourth molecular speciesand characterization of alternative splicing of RNA.Molecularendocrinology.1991;5(12):1806-14.Epub 1991 / 12 / 01.

[0255] Hynes NE,Lane HA.ERBB receptors and cancer:the complexity oftargetedinhibitors.Nature reviews Cancer.2005;5(5):341-54.

[0256] Ishida Y,Agata Y,Shibahara K,Honjo T.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.TheEMBO journal.1992:11(11):3887-95.

[0257] Iwai Y,Ishida M,Tanaka Y,Okazaki T,Honjo T,Minato N.Involvement ofPD-L1on tumor cells in the escape from host immune system and tumorimmunotherapy by PD-L1 blockade.2002:99(19):12293-7.

[0258] Jain RK,Duda DG,Clark JW,Loeffler JS.Lessons from phase III clinical trials of anti-VEGF therapy for cancer.Nat Clin Pract Oncol.2006:3(1):24-40.

[0259] Karplus PA,Schulz GE.Refined structure of glutathione reductase at 1.54 resolution.Journal of molecular biology.1987:195(3):701-29.

[0260] Kaumaya PT,Foy KC,Garrett J,Rawale SV,Vicari D,Thurmond JM,Lamb T,ManiA,Kane Y,Balint CR,Chalupa D,Otterson GA,Shapiro CL,Fowler JM,Grever MR,Bekaii-Saab TS,Carson WE,3rd.Phase I active immunotherapy with combination oftwo chimeric,human epidermal growth factor receptor 2,B-cell epitopes fusedto apromiscuous T-cell epitope in patients with metastatic and / or recurrentsolid tumors.J ClinOncol.2009;27(31):5270-7.

[0261] Kaumaya PT.A paradigm shift:Cancer therapy with peptide-based B-cellepitopesand peptide immunotherapeutics targeting multiple solid tumor types:Emerging conceptsand validation of combination immunotherapy.Human vaccines&immunotherapeutics.2015;11(6):1368-86.

[0262] Kaumaya PT.Could precision-engineered peptide epitopes / vaccines bethe key to acancer cure?Future Oncol.2011;7(7):807-10.

[0263] Kaumaya PTP,Kobs-Conrad S,DiGeorge AM,Stevens V.Denovo EngineeringofProtein Immunogenic&Antigenic Determinants.In:Anantharamaiah GMB,C.,editor.PEPTIDES:Springer-Verlag.;1994.p.133-64.

[0264] Kaumaya PTP.HER-2 / neu cancer vaccines:Present status andfutureprospects.International Journal of Peptide Research andTherapeutics.2006;12(1):65-77.

[0265] Kyte J,Doolittle RF.A simple method for displaying the hydropathiccharacter of aprotein.Journal of molecular biology.1982;157(1):105-32.

[0266] Li B,Ogasawara AK,Yang R,Wei W,He GW,Zioncheck TF,Bunting S,de VosAM,Jin H.KDR(VEGF receptor 2)is the major mediator for the hypotensive effectof VEGF.Hypertension.2002;39(6):1095-100.Epub 2002 / 06 / 08.

[0267] Lynch MP,Kaumaya PTP.Advances in HTLV-1peptide vaccines andtherapeutics.Current Protein and Peptide Science.2006;7(2):137-45.

[0268] Miller MJ,Foy KC,Kaumaya PT.Cancer immunotherapy:present status,future perspective,and a new paradigm of peptide immunotherapeutics.Discoverymedicine.2013;15(82):166-76.Epub 2013 / 04 / 03.

[0269] Miller MJ,Foy KC,Kaumaya PTP.Cancer immunotherapy:Present status,future perspective,and a new paradigm of peptide immunotherapeutics.Discoverymedicine.2013;15(82):166-76.

[0270] Motzer RJ,Rini BI,McDermott DF,Redman BG,Kuzel TM,Harrison MR,Vaishampayan UN,Drabkin HA,George S,Logan TF,Margolin KA,Plimack ER,LambertAM,Waxman IM,Hammers HJ.Nivolumab for Metastatic Renal Cell Carcinoma:Resultsof a Randomized Phase II Trial.Journal of clinical oncology:official journalof the American Society of Clinical Oncology.2015;33(13):1430-7.

[0271] Nelson AL,Dhimolea E,Reichert JM.Development trends for humanmonoclonal antibody therapeutics.Nature reviews Drug discovery.2010;9(10):767-74.

[0272] Novotny J, Handschumacher M, Haber E, Bruccoleri RE, Carlson WB, Fanning DW, Smith JA, Rose GD. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proceedings of the National Academy of Sciences of the United States of America. 1986;83(2):226 - 30.

[0273] Oshima RG, Lesperance J, Munoz V, Hebbard L, Ranscht B, Sharan N, Muller WJ, Hauser CA, Cardiff RD. Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Res. 2004;64(1):169 - 79. Epub 2004 / 01 / 20.

[0274] Preston, C.C., et al., The ratios of CD8+ T cells to CD4+CD25+FOXP3+ and FOXP3 - T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One, 2013.8(11):p.e80063.

[0275] Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C,Dowlati A,Sanborn R,Lopez-Chavez A,Grohe C,Huber RM,Harbison CT,Baudelet C,Lestini BJ,Ramalingam SS.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate). 063):a phase 2,single-arm trial.The LancetOncology.2015:16(3):257-65.

[0276] Rose GD,Geselowitz AR,Lesser GJ,Lee RH,Zehfus MH.Hydrophobicity ofaminoacid residues in globular proteins.Science.1985:229(4716):834-8.

[0277] Roskoski R,Jr.The ErbB / HER family of protein-tyrosine kinasesandcancer.2014:79:34-74.Epub 2013 / 11 / 26.

[0278] Sharma P,Allison JP.The future of immune checkpointtherapy.Science.2015;348(6230):56-61.

[0279] Shinohara T,Taniwaki M,Ishida Y,Kawaichi M,Honjo T.Structureandchromosomal localization of the human PD-1 gene(PDCD1).Genomics.1994;23(3):704-6.

[0280] Srinivasan M,Gienapp IE,Stuckman SS,Rogers CJ,Jewell SD,Kaumaya PT,Whitacre CC.Suppression of experimental autoimmune encephalomyelitis usingpeptidemimics of CD28.J Immunol.2002;169(4):2180-8.Epub 2002 / 08 / 08.

[0281] Srinivasan M,Wardrop RM,Gienapp IE,Stuckman SS,Whitacre CC,KaumayaPT.A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motifadopts apolyproline type II helix and inhibits encephalitogenic T cells invitro.J Immunol.2001;167(1):578-85.

[0282] Steele JT,Allen SD,Kaumaya PTP.Cancer Immunotherapy with RationallyDesignedSynthetic Peptides.Handbook of Biologically ActivePeptides2006.p.491-8.

[0283] Sundaram R,Dakappagari NK,Kaumaya PTP.Synthetic peptides ascancervaccines.Biopolymers-Peptide Science Section.2002;66(3):200-16.

[0284] Thornton JM,Edwards MS,Taylor WR,Barlow DJ.Location of'continuous'antigenic determinants in the protruding regions of proteins.The EMBOjournal.1986;5(2):409-13.

[0285] Topalian SL,Drake CG,Pardoll DM.Immune checkpoint blockade:a commondenominator approach to cancer therapy.Cancer cell.2015;27(4):450-61.

[0286] Topalian SL,Hodi FS,Brahmer JR,Gettinger SN,Smith DC,McDermott DF,Powderly JD,Carvajal RD,Sosman JA,Atkins MB,Leming PD,Spigel DR,Antonia SJ,Horn L,Drake CG,Pardoll DM,Chen L,Sharfman WH,Anders RA,Taube JM,McMiller TL,Xu H,Korman AJ,Jure-Kunkel M,Agrawal S,McDonald D,Kollia GD,Gupta A,WiggintonJM,Sznol M.Safety,activity,and immune correlates of anti-PD-1antibody incancer.The New England journal of medicine.2012;366(26):2443-54.

[0287] Vicari D,Foy KC,Liotta EM,Kaumaya PT.Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF SignalingPathways.J Biol Chem.286(15):13612-25.Epub 2011 / 02 / 16.

[0288] Wang B,Kaumaya PT,Cohn DE.Immunization with synthetic VEGF peptidesin ovarian cancer.Gynecol Oncol.2010;119(3):564-70.

[0289] Welling GW,Weijer WJ,van der Zee R,Welling-Wester S.Prediction ofsequential antigenic regions in proteins.FEBS letters.1985;188(2):215-8.

[0290] Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network.Naturereviews Molecular cell biology.2001;2(2):127-37.Epub 2001 / 03 / 17.

[0291] Zak KM,Kitel R,Przetocka S,Golik P,Guzik K,Musielak B,Domling A,DubinG,Holak TA.Structure of the Complex of Human Programmed Death 1,PD-1,and ItsLigand PD-L1.Structure.2015;23(12):2341-8.

[0292] Zhu Z,Witte L.Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascularendothelial growth factor.1999:17(3):195-212.Epub2000 / 02 / 09.

[0293] F.Sequence

[0294] SEQ ID NO:1of PD1 fragment 1-128

[0295] PPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKLQIKESLRAERVTERRAEVPTAHPSPSP

[0296] SEQ ID NO:2PD1(32-50)

[0297] VLNWYRMSPSNQTDCLAF

[0298] SEQ ID NO:3PD1(45-64)

[0299] KLAAFPEDRSQPGQDCRFR

[0300] SEQ ID NO:4PD1(73-90)

[0301] DFHMSVVRARRNDSGTYL

[0302] SEQ ID NO:5PD1(92-110)

[0303] GAISLAPKAQIKESLRAEL

[0304] SEQ ID NO:6-membered variant fragment(MVF)

[0305] KLLSLIKGVIVHRLEGVE

[0306] SEQ ID NO:7FLORA

[0307] GPSL

[0308] SEQ ID NO:8MVF-PD1(32-50)

[0309] KLLSLIKGVIVHRLEGVEGPSLVLNWYRMSPSNQTDKLAAF

[0310] SEQ ID NO:9MVF-PD1(45-64)

[0311] KLLSLIKGVIVHRLEGVEGPSLKLAAFPEDRSQPGQDCRFR

[0312] SEQ ID NO:10MVF-PD1(73-90)

[0313] KLLSLIKGVIVHRLEGVEGPSLDFHMSVVRARRNDSGTYL

[0314] SEQ ID NO:11MVF-PD1(92-110)

[0315] KLLSLIKGVIVHRLEGVEGPSLGAISLAPKAQIKESLRAEL

[0316] SEQ ID NO: 12PD1(32-50)D peptide reverse-flip form

[0317] FAALKDTQNSPSMRYWNLV

[0318] SEQ ID NO: 13 PD1(45-64)D peptide reverse-flip form

[0319] RFRCDQGPQSRDEPFAALK

[0320] SEQ ID NO: 14 PD1(73-90)D peptide reverse-flip form

[0321] LYTGSDNRRARVVSMHFD

[0322] SEQ ID NO: 15 PD1 (92-110) D peptide reverse-flip form

[0323] LEARLSEKIQAKPALSIAG

[0324] SEQ ID NO: 16MVF PD1(32-50)D peptide reverse-flip form

[0325] KLLSLIKGVIVHRLEGVEGPSLFAALKDTQNSPSMRYWNLV

[0326] SEQ ID NO: 17 MVF PD1 (45-64) D peptide reverse-flip form

[0327] KLLSLIKGVIVHRLEGVEGPSLRFRCDQGPQSRDEPFAALK

[0328] SEQ ID NO: 18 MVF PD1 (73-90) D peptide reverse-flip form

[0329] KLLSLIKGVIVHRLEGVEGPSLLYTGSDNRRARVVSMHFD

[0330] SEQ ID NO: 19 MVF PD1 (92-110) D peptide reverse-flip form

[0331] KLLSLIKGVIVHRLEGVEGPSLLEARLSEKIQAKPALSIAG

[0332] SEQ ID NO:20TT

[0333] NSVDDALINSTIYSYFPSV

[0334] SEQ ID NO:21TT1

[0335] PGINGKAIHLVNNQSSE

[0336] SEQ ID NO:22P2

[0337] QYIKANSKFIGITEL

[0338] SEQ ID NO:23P30

[0339] FNNFTVSFWLRVPKVSASHLE

[0340] SEQ ID NO: 24MVF (natural)

[0341] LSEIKGVIVHRLEGV

[0342] SEQ ID NO:25HBV

[0343] FFLLTRILTIPQSLN

[0344] SEQ ID NO:26CSP

[0345] TCGVGVRVRSRVNAANKKPE

[0346] SEQ ID NO:27HER-2(266-296)

[0347] LHCPALVTYNTDTFESMPNPEGRYTFGASCV

[0348] SEQ ID NO:28MVF HER-2(266-296)

[0349] KLLSLIKGVIVHRLEGVEGPSLLHCPALVTYNTDTFESMPNPEGRYTFGASCV

[0350] SEQ ID NO:29HER-2(597-626)

[0351] VARCPSGVKPDLSYMPIWKFPDEEGACQPL

[0352] SEQ ID NO:30MVF HER-2(597-626)

[0353] KLLSLIKGVIVHRLEGVEGPSLVARCPSGVKPDLSYMPIWKFPDEEGACQPL

Claims

1. An isolated peptide consisting of the amino acid sequence of SEQ ID NO: 5.